View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2012	Feb. 15, 2013	Jun. 30, 2012
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q4
Entity Registrant Name	Lilly Eli & Co
Entity Central Index Key	0000059478
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 42,793,000,000
Entity Common Stock, Shares Outstanding		1,134,411,762

Consolidated Statements of Operations - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenue	$ 22,603.4	$ 24,286.5	$ 23,076.0
Cost of sales	4,796.5	5,067.9	4,366.2
Research and development	5,278.1	5,020.8	4,884.2
Marketing, selling, and administrative	7,513.5	7,879.9	7,053.4
Acquired in-process research and development	0.0	388.0	50.0
Asset impairments, restructuring, and other special charges	281.1	401.4	192.0
Other-net, (income) expense	674.0	(179.0)	(5.0)
Cost of sales, operating expenses, and other-net	17,195.2	18,937.0	16,550.8
Income before income taxes	5,408.2	5,349.5	6,525.2
Income taxes	1,319.6	1,001.8	1,455.7
Net income	$ 4,088.6	$ 4,347.7	$ 5,069.5
Earnings per share - basic	$ 3.67	$ 3.90	$ 4.58
Earnings per share - diluted	$ 3.66	$ 3.90	$ 4.58

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Net income	$ 4,088.6	$ 4,347.7	$ 5,069.5
Other comprehensive income (loss)
Foreign currency translation gains (losses)	160.9	(244.8)	(325.1)
Net unrealized gains (losses) on securities	88.5	(178.5)	80.8
Defined benefit pension and retiree health benefit plans	128.6	1,240.2	(148.9)
Effective portion of cash flow hedges	8.7	44.8	(26.6)
Other comprehensive income (loss) before income taxes	129.5	(1,618.7)	(122.0)
Provision for income taxes related to other comprehensive income (loss) items	(68.0)	430.2	(76.2)
Other comprehensive income (loss)	61.5	(1,188.5)	(198.2)
Comprehensive income	$ 4,150.1	$ 3,159.2	$ 4,871.3

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2012	Dec. 31, 2011
Current Assets
Cash and cash equivalents	$ 4,018.8	$ 5,922.5
Short-term investments	1,665.5	974.6
Accounts receivable, net of allowances of $108.5 (2012) and $110.1 (2011)	3,336.3	3,597.7
Other receivables	552.0	640.2
Inventories	2,643.8	2,299.8
Prepaid expenses and other	822.3	813.4
Total current assets	13,038.7	14,248.2
Other Assets
Investments	6,313.3	4,029.8
Goodwill and other intangibles - net	4,752.7	5,128.1
Sundry	2,534.0	2,493.4
Total other assets	13,600.0	11,651.3
Property and equipment, net	7,760.2	7,760.3
Total assets	34,398.9	33,659.8
Current Liabilities
Short-term borrowings and current maturies of long-term debt	11.9	1,522.3
Accounts payable	1,188.3	1,125.2
Employee compensation	940.3	804.7
Sales rebates and discounts	1,777.2	1,771.3
Dividends payable	541.4	542.3
Income taxes payable	143.5	261.6
Deferred income taxes	1,048.0	422.3
Other current liabilities	2,738.9	2,481.2
Total current liabilities	8,389.5	8,930.9
Other Liabilities
Long-term debt	5,519.4	5,464.7
Accrued retirement benefits	3,012.4	3,068.5
Long-term income taxes payable	1,334.3	1,086.3
Other noncurrent liabilities	1,369.4	1,573.8
Total other liabilities	11,235.5	11,193.3
Shareholders' Equity
Common stock	716.6	724.1
Additional paid-in capital	4,963.1	4,886.8
Retained earnings	16,088.2	14,897.8
Employee benefit trust	(3,013.2)	(3,013.1)
Accumulated other comprehensive loss	(3,797.1)	(3,858.6)
Noncontrolling interests	8.7	(6.1)
Cost of common stock in treasury	(192.4)	(95.3)
Total shareholders' equity	14,773.9	13,535.6
Total liabilities and shareholders' equity	$ 34,398.9	$ 33,659.8

Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Millions	Dec. 31, 2012	Dec. 31, 2011
Accounts receivable, allowances	$ 108.5	$ 110.1
Issued shares, shares in thousands	1,146,493	1,158,644
Common stock shares in treasury, shares in thousands	2,850	853

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash Flows from Operating Activities
Net income	$ 4,088.6	$ 4,347.7	$ 5,069.5
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,462.2	1,373.6	1,328.2
Changes in deferred income taxes	126.0	(268.5)	559.7
Stock-based compensation expense	141.5	147.4	231.0
Impairment charges, indefinite lived intangibles	205.0	151.5	0.0
Acquired in-process research and development, net of tax	0.0	252.2	32.5
Income related to prepayment of revenue-sharing obligation	(787.8)	0.0	0.0
Other operating activities, net	120.5	(17.8)	(178.6)
Changes in operating assets and liabilities, net of acquisitions
Receivables - (increase) decrease	361.8	(188.8)	(319.1)
Inventories - (increase) decrease	(307.9)	203.1	157.0
Other assets - (increase) decrease	231.0	642.7	340.5
Accounts payable and other liabilties-increase (decrease)	(336.1)	591.4	(363.9)
Net Cash Provided by Operating Activities	5,304.8	7,234.5	6,856.8
Cash Flows from Investing Activities
Purchases of property and equipment	(905.4)	(672.0)	(694.3)
Disposals of property and equipment	22.0	25.3	24.6
Net change in short-term investments	375.1	(250.9)	(686.5)
Proceeds from sales and maturities of noncurrent investments	4,355.7	2,138.5	584.7
Purchases of noncurrent investments	(7,618.6)	(4,459.4)	(1,067.2)
Purchase of product rights	(138.8)	(632.9)	(442.4)
Purchases of in-process research and development	0.0	(388.0)	(50.0)
Cash paid for acquisition, net of cash acquired	(199.3)	(307.8)	(609.4)
Net change in loan to collaboration partner	165.0	(165.0)	0.0
Proceeds from prepayment of revenue-sharing obligation	1,212.1	0.0	0.0
Other investing activities, net	(100.6)	(112.2)	(219.3)
Net Cash Used for Investing Activities	(2,832.8)	(4,824.4)	(3,159.8)
Cash Flows from Financing Activities
Dividends paid	(2,187.4)	(2,180.1)	(2,165.3)
Net change in short-term borrowings	(10.5)	(141.2)	125.1
Repayments of long-term debt	(1,500.6)	(54.6)	(1.1)
Purchases of common stock	(721.1)	0.0	0.0
Other financing activities, net	0.0	6.0	19.4
Net Cash Used for Financing Activities	(4,419.6)	(2,369.9)	(2,021.9)
Effect of exchange rate on cash and cash equivalents	43.9	(110.9)	(144.8)
Net increase (decrease) in cash and cash equivalents	(1,903.7)	(70.7)	1,530.3
Cash and cash equivalents at beginning of year	5,922.5	5,993.2	4,462.9
Cash and Cash Equivalents at End of Year	$ 4,018.8	$ 5,922.5	$ 5,993.2

Segment Information

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Segment Information

We operate in two business segments—human pharmaceutical products and animal health. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The accounting policies of the individual segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements.

Our human pharmaceutical products segment includes the discovery, development, manufacturing, marketing, and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular, and other. Our neuroscience group of products includes Cymbalta, Zyprexa, Strattera, and Prozac. Endocrinology products consist primarily of Humalog, Humulin, Forteo, Evista, Humatrope, Byetta, and Actos. Oncology products consist primarily of Alimta, Erbitux, and Gemzar. Cardiovascular products consist primarily of Cialis, Effient, and ReoPro. The other pharmaceuticals category includes anti-infectives, primarily Vancocin and Ceclor, and other miscellaneous pharmaceutical products and services.

Our animal health segment, operating through our Elanco animal health division, includes the development, manufacturing, marketing, and sales of animal health products worldwide for both food and companion animals. Animal health products include Rumensin, Tylan, Posilac, Paylean, and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals.

Most of our pharmaceutical products are distributed through wholesalers that serve pharmacies, physicians and other health care professionals, and hospitals. For the years ended December 31, 2012, 2011, and 2010, our three largest wholesalers each accounted for between 10 percent and 16 percent of consolidated total revenue. Further, they each accounted for between 9 percent and 14 percent of accounts receivable as of December 31, 2012 and 2011. Animal health products are sold primarily to wholesale distributors.

We manage our assets on a total company basis, not by operating segment, as the assets of the animal health business are intermixed with those of the pharmaceutical products business. Therefore, our chief operating decision maker does not review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

We are exposed to the risk of changes in social, political, and economic conditions inherent in foreign operations, and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31	2012			2011			2010
Segment revenue—to unaffiliated customers
Human pharmaceutical products
Neuroscience		$	7,575.1		$	9,723.8		$	9,419.0
Endocrinology		6,810.9			6,806.7			6,135.4
Oncology		3,281.6			3,322.2			3,744.5
Cardiovascular		2,632.5			2,486.4			2,171.3
Other pharmaceuticals		266.8			268.8			214.4
Total human pharmaceutical products		20,566.9			22,607.9			21,684.6
Animal health		2,036.5			1,678.6			1,391.4
Total segment revenue		$	22,603.4		$	24,286.5		$	23,076.0

Segment profits
Human pharmaceutical products		$	4,393.4		$	5,837.9		$	6,516.3
Animal health		508.1			301.0			250.9
Total segment profits		$	4,901.5		$	6,138.9		$	6,767.2

Reconciliation of total segment profits to consolidated income before taxes
Segment profits		$	4,901.5		$	6,138.9		$	6,767.2
Other profits (losses)
Income related to prepayment of Amylin's obligation (Note 4)		787.8			—			—
Acquired in-process research and development (Notes 3 and 4)		—			(388.0		)	(50.0		)
Asset impairments, restructuring, and other special charges (Note 5)		(281.1		)	(401.4		)	(192.0		)
Total consolidated income before taxes		$	5,408.2		$	5,349.5		$	6,525.2

For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical products segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global service centers, certain acquisition-related transaction costs, and inventory valuation adjustments.



(Dollars in millions)	Year Ended December 31	2012		2011		2010
Geographic Information
Revenue—to unaffiliated customers⁽¹⁾
United States		$	12,313.1	$	12,977.2	$	12,865.6
Europe		4,259.7		5,290.9		5,106.4
Japan		2,246.2		2,104.1		1,616.6
Other foreign countries		3,784.4		3,914.3		3,487.4
Revenue		$	22,603.4	$	24,286.5	$	23,076.0

Long-lived assets⁽²⁾
United States		$	5,064.7	$	5,485.3	$	5,333.9
Europe		2,281.1		2,220.2		2,250.7
Japan		101.5		102.9		101.2
Other foreign countries		1,543.2		1,564.0		1,588.4
Long-lived assets		$	8,990.5	$	9,372.4	$	9,274.2


¹	Revenue is attributed to the countries based on the location of the customer.


²	Long-lived assets consist of property and equipment and certain sundry assets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

Basis of Presentation [Text Block]

Note 1: Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The accounts of all wholly-owned and majority-owned subsidiaries are included in the consolidated financial statements. Where our ownership of consolidated subsidiaries is less than 100 percent, the noncontrolling shareholders’ interests are reflected in shareholders’ equity. All intercompany balances and transactions have been eliminated.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing.

All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of dilutive stock options and other incremental shares.

Cash equivalents

We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

Inventories

We state all inventories at the lower of cost or market. We use the last-in, first-out (LIFO) method for the majority of our inventories located in the continental United States, or approximately 40 percent of our total inventories. Other inventories are valued by the first-in, first-out (FIFO) method. FIFO cost approximates current replacement cost. Inventories at December 31 consisted of the following:



	2012			2011
Finished products	$	834.4		$	786.4
Work in process	1,735.8			1,518.2
Raw materials and supplies	256.1			205.8
	2,826.3			2,510.4
Reduction to LIFO cost	(182.5		)	(210.6		)
Inventories	$	2,643.8		$	2,299.8

Investments

Substantially all of our investments in debt and marketable equity securities are classified as available-for-sale. Investment securities with maturity dates of less than one year from the date of the balance sheet are classified as short-term. Available-for-sale securities are carried at fair value with the unrealized gains and losses, net of tax, reported in other comprehensive income (loss). The credit portion of unrealized losses on our debt securities considered to be other-than-temporary is recognized in earnings. The remaining portion of the other-than-temporary impairment on our debt securities is then recorded in other comprehensive income (loss). The entire amount of other-than-temporary impairment on our equity securities is recognized in earnings. We do not evaluate cost-method investments for impairment unless there is an indicator of impairment. We review these investments for indicators of impairment on a regular basis. Realized gains and losses on sales of available-for-sale securities are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings. Investments in companies over which we have significant influence but not a controlling interest are accounted for using the equity method with our share of earnings or losses reported in other—net, (income) expense. We own no investments that are considered to be trading securities.

Risk-management instruments

Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and do not create additional risk because gains and losses on derivative contracts offset losses and gains on the assets, liabilities, and transactions being hedged. As derivative contracts are initiated, we designate the instruments individually as either a fair value hedge or a cash flow hedge. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis.

For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive income (loss) and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change.

We may enter into foreign currency forward contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other—net, (income) expense. We may enter into foreign currency forward contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.

In the normal course of business, our operations are exposed to fluctuations in interest rates. These fluctuations can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance.

Interest rate swaps or collars that convert our fixed-rate debt or investments to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt or investments to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements.

We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities.

Goodwill and other intangibles

Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized.

Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years.

The cost of in-process research and development (IPR&D) projects acquired directly in a transaction other than a business combination is capitalized if the projects have an alternative future use; otherwise, they are expensed. The fair values of IPR&D projects acquired in business combinations are capitalized as other intangible assets. Several methods may be used to determine the estimated fair value of the IPR&D acquired in a business combination. We utilize the “income method,” which applies a probability weighting that considers the risk of development and commercialization, to the estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products, and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each project independently. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. We also capitalize milestone payments incurred at or after the product has obtained regulatory approval for marketing and amortize those amounts over the remaining estimated useful life of the underlying asset.

Goodwill and indefinite-lived intangible assets are reviewed for impairment at least annually and when certain impairment indicators are present. When required, a comparison of fair value to the carrying amount of assets is performed to determine the amount of any impairment. When determining the fair value of indefinite-lived IPR&D assets for impairment testing purposes, we utilize the "income method" discussed in the previous paragraph. Finite-lived intangible assets are reviewed for impairment when an indicator of impairment is present.

Property and equipment

Property and equipment is stated on the basis of cost. Provisions for depreciation of buildings and equipment are computed generally by the straight-line method at rates based on their estimated useful lives (12 to 50 years for buildings and 3 to 18 years for equipment). We review the carrying value of long-lived assets for potential impairment on a periodic basis and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Impairment is determined by comparing projected undiscounted cash flows to be generated by the asset to its carrying value. If an impairment is identified, a loss is recorded equal to the excess of the asset’s net book value over its fair value, and the cost basis is adjusted.

At December 31, property and equipment consisted of the following:



	2012			2011
Land	$	201.4		$	202.5
Buildings	6,373.8			6,135.7
Equipment	7,542.9			7,219.9
Construction in progress	799.9			1,036.0
	14,918.0			14,594.1
Less accumulated depreciation	(7,157.8		)	(6,833.8		)
Property and equipment, net	$	7,760.2		$	7,760.3

Depreciation expense for the years ended December 31, 2012, 2011, and 2010 was $754.0 million, $732.4 million, and $749.1 million, respectively. Interest costs of $21.0 million, $25.7 million, and $26.0 million were capitalized as part of property and equipment for the years ended December 31, 2012, 2011, and 2010, respectively. Total rental expense for all leases, including contingent rentals (not material), amounted to $285.8 million, $267.4 million, and $255.7 million for the years ended December 31, 2012, 2011, and 2010, respectively. Assets under capital leases included in property and equipment in the consolidated balance sheets, capital lease obligations entered into, and future minimum rental commitments are not material.

Litigation and environmental liabilities

Litigation accruals and environmental liabilities and the related estimated insurance recoverables are reflected on a gross basis as liabilities and assets, respectively, on our consolidated balance sheets. With respect to the product liability claims currently asserted against us, we have accrued for our estimated exposures to the extent they are both probable and reasonably estimable based on the information available to us. We accrue for certain product liability claims incurred but not filed to the extent we can formulate a reasonable estimate of their costs. We estimate these expenses based primarily on historical claims experience and data regarding product usage. Legal defense costs expected to be incurred in connection with significant product liability loss contingencies are accrued when probable and reasonably estimable. A portion of the costs associated with defending and disposing of these suits is covered by insurance. We record receivables for insurance-related recoveries when it is probable they will be realized. These receivables are classified as a reduction of the litigation charges on the statement of operations. We estimate insurance recoverables based on existing deductibles, coverage limits, our assessment of any defenses to coverage that might be raised by the carriers, the financial condition of the insurers, and the possibility of and length of time for collection. For substantially all of our currently marketed products, we are completely self-insured for product liability losses.

Revenue recognition

We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. Provisions for returns, discounts, and rebates are established in the same period the related sales are recorded.

We also generate income as a result of collaboration agreements. Revenue from co-promotion services is based upon net sales reported by our co-promotion partners and, if applicable, the number of sales calls we perform. Initial fees we receive from the partnering of our compounds under development where we have continuing involvement are generally amortized through the expected product approval date. Initial fees received from out-licensing agreements that include both the sale of marketing rights to our commercialized products and a related commitment to supply the products are generally recognized in net product sales over the term of the supply agreement. We immediately recognize the full amount of developmental milestone payments due to us upon the achievement of the milestone event if the event is substantive, is objectively determinable, and represents an important point in the development life cycle of the pharmaceutical product. Milestone payments earned by us are generally recorded in other—net, (income) expense. If the payment to us is a commercialization payment that is part of a multiple-element collaborative commercialization arrangement and is a result of the initiation of the commercialization period (e.g., payments triggered by regulatory approval for marketing or launch of the product), we amortize the payment to income as we perform under the terms of the arrangement. See Note 4 for specific agreement details.

Royalty revenue from licensees, which is based on third-party sales of licensed products and technology, is recorded as earned in accordance with the contract terms when third-party sales can be reasonably measured and collection of the funds is reasonably assured. This royalty revenue is included in collaboration and other revenue.

Following is the composition of revenue:



	2012		2011		2010
Net product sales	$	21,970.4	$	23,604.8	$	22,442.2
Collaboration and other revenue (Note 4)	633.0		681.7		633.8
Total revenue	$	22,603.4	$	24,286.5	$	23,076.0

Research and development expenses and acquired research and development

Research and development expenses include the following:


•	Research and development costs, which are expensed as incurred.


•	Milestone payments incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Acquired IPR&D expense includes the initial costs of IPR&D projects acquired directly in asset acquisitions, unless they have an alternative future use.

Income taxes

Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. Federal income taxes are provided on the portion of the income of foreign subsidiaries that is expected to be remitted to the United States and be taxable.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.

Earnings per share

We calculate basic earnings per share based on the weighted-average number of common shares outstanding and incremental shares. We calculate diluted earnings per share based on the weighted-average number of common shares outstanding, including incremental shares and stock options. See Note 12 for further discussion.

Stock-based compensation

We recognize the fair value of stock-based compensation as expense over the requisite service period of the individual grantees, which generally equals the vesting period. Under our policy, all stock-based awards are approved prior to the date of grant. The compensation committee of the board of directors approves the value of the award and date of grant. Stock-based compensation that is awarded as part of our annual equity grant is made on a specific grant date scheduled in advance.

Reclassifications

Certain reclassifications have been made to prior periods in the consolidated financial statements and accompanying notes to conform with the current presentation.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Implementation of New Financial Accounting Pronouncements	12 Months Ended
	Dec. 31, 2012
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Accounting Changes and Error Corrections [Text Block]	Note 2: Implementation of New Financial Accounting Pronouncements In 2010, the Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) that applies to the annual fee imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs as part of U.S. health care reform. This fee is allocated to companies based on their prior-calendar-year market share for branded prescription drug sales into these government programs. In accordance with the ASU, we record this fee as marketing, selling, and administrative expense in our consolidated results of operations and amortize it on a straight-line basis for the year. This guidance was effective for us January 1, 2011. For the years ended December 31, 2012 and 2011, we recorded $170.7 million and $178.0 million, respectively, related to this fee, which is not deductible for tax purposes.

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References + Details

Acquisitions	12 Months Ended
Acquisitions	Dec. 31, 2012
Business Combinations [Abstract]
Acquisitions [Text Block]	Note 3: Acquisitions From 2010 to 2012, we completed the acquisitions of ChemGen Corporation (ChemGen), the animal health business of Janssen Pharmaceuticia NV (Janssen), Avid Radiopharmaceuticals, Inc. (Avid), Alnara Pharmaceuticals, Inc. (Alnara), and a group of animal health product lines. These acquisitions were accounted for as business combinations under the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition. None of these acquisitions were material to our consolidated financial statements. These acquisitions included IPR&D, which represented compounds, new indications, or line extensions under development that had not yet achieved regulatory approval for marketing. As discussed in Note 1, the fair values of IPR&D assets acquired as part of the acquisition of a business are capitalized as intangible assets. We capitalized $1.6 million, $29.6 million, and $598.0 million of IPR&D assets that were acquired in business combinations during the years ended December 31, 2012, 2011, and 2010, respectively. The ongoing expenses with respect to each of these assets in development are not material to our total research and development expense currently and are not expected to be material to our total research and development expense on an annual basis in the future. Some of these acquisitions included contingent consideration, which is recorded at fair value in other liabilities as of the acquisition date. The fair value of the contingent consideration was determined by utilizing a probability weighted estimated cash flow stream discounted for the expected timing of each payment. In addition to the acquisitions of businesses, we also acquired several assets in development during 2011 and 2010, which are discussed below in Product Acquisitions and in Note 4. The acquired IPR&D related to these products of $388.0 million and $50.0 million for the years ended December 31, 2011, and 2010, respectively, was written off by a charge to income immediately upon acquisition because the products had no alternative future use. In connection with the arrangements described below, our partners may be entitled to future milestones and royalties based on sales should these products be approved for commercialization. Acquisition of Businesses ChemGen On February 17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed-enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of $206.9 million in cash. In connection with this acquisition, we preliminarily recorded $151.5 million of marketed product assets, with $55.4 million of other net assets. The final determination may result in asset and liability fair values that differ from the preliminary estimates, but it is not expected that these differences will be material to our consolidated financial statements. Janssen On July 7, 2011, we acquired the animal health business of Janssen, a Johnson & Johnson company, for total purchase consideration of $307.8 million in cash. We obtained a portfolio of more than 50 marketed animal health products. In connection with this acquisition, we recorded $234.4 million of marketed product assets and $29.6 million of acquired IPR&D assets, with $43.8 million of other net assets. Avid On December 20, 2010, we acquired all of the outstanding stock of Avid, a company focusing on developing molecular radiopharmaceutical tracers in positron emission tomography (PET) scan imaging, for total purchase consideration of $346.1 million, which included an upfront payment of $286.3 million and up to $550 million in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was $59.8 million. In connection with this acquisition, we recorded $334.0 million of acquired IPR&D assets, $119.6 million of goodwill, and $116.9 million of deferred tax liability, with $9.4 million of other net assets. Avid’s lead product, Amyvid, is a PET agent indicated for imaging amyloid plaque pathology in the brain to aid the evaluation of patients with signs or symptoms of cognitive impairment. During the year ended December 31, 2011, we recorded impairment charges for the IPR&D asset related to Amyvid, as discussed further in Note 7. Amyvid received regulatory approval in the U.S. in 2012 and European Union in 2013, and is available to a limited number of imaging centers. Alnara On July 20, 2010, we acquired all of the outstanding stock of Alnara, a privately-held company developing protein therapeutics for the treatment of metabolic diseases, for total purchase consideration of $291.7 million, which included an upfront payment of $188.7 million and up to $200 million in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was $103.0 million. In connection with this acquisition, we recorded $264.0 million of acquired IPR&D assets, $100.5 million of goodwill, and $92.4 million of deferred tax liability, with $19.6 million of other net assets. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy. The New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in the first quarter of 2010. In April 2011, we received a complete response letter that communicated the need for us to conduct an additional clinical trial prior to a resubmission. During the years ended December 31, 2012 and 2011, we recorded impairment charges for the IPR&D asset related to liprotamase, as discussed further in Note 7. Animal Health Product Lines On May 28, 2010, we acquired the European marketing rights to several animal health product lines divested by Pfizer Inc., for total purchase consideration of $148.4 million paid in cash. These products, including vaccines, parasiticides, and feed additives, serve both the production animal and companion animal markets. We also acquired a manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. In connection with this acquisition, we recorded $76.2 million of marketed product intangible assets, with $72.2 million of other net assets. Product Acquisitions In March 2010, we entered into a license agreement with Acrux Limited to acquire the exclusive rights to commercialize its proprietary testosterone solution Axiron. At the time of the licensing, the product had not been approved and had no alternative future use. The charge of $50.0 million for acquired IPR&D related to this arrangement was included as expense in the first quarter of 2010 and is deductible for tax purposes. In the fourth quarter of 2010, Axiron was approved by the FDA for the treatment of testosterone deficiency in men. In the first quarter of 2011, the product was available in pharmacies in the United States.

Collaborations

12 Months Ended

Dec. 31, 2012

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations [Text Block]

Note 4: Collaborations

We often enter into collaborative arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These collaborations often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the third party. Revenues related to products sold by us pursuant to these arrangements are included in net product sales, while other sources of revenue (e.g., royalties and profit-share payments) are included in collaboration and other revenue. Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments made to or reimbursements received from our collaboration partners. Each collaboration is unique in nature, and our more significant arrangements are discussed below.

Exenatide

In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta (exenatide injection) and other forms of exenatide such as Bydureon (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million. Amylin also agreed to make future revenue-sharing payments to us in an amount equal to 15.0 percent of their global net sales of exenatide products until Amylin made aggregate payments to us of $1.20 billion plus interest, which would accrue at 9.5 percent. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb in August 2012, Amylin's obligation of $1.26 billion, including accrued interest, was paid in full, with $1.21 billion representing a prepayment of the obligation. Amylin will also pay a $150.0 million milestone to us contingent upon FDA approval of a once-monthly suspension version of exenatide that is currently in Phase II clinical trials.

Commercial operations were transferred to Amylin in the U.S. at the end of November 2011. Outside the U.S., we anticipate transferring responsibility for commercialization of exenatide to Amylin in substantially all markets at the end of the first quarter of 2013.

Payments received from Amylin were allocated 65 percent to the U.S., which was treated as a contract termination, and 35 percent to the business outside the U.S., which will be treated as the disposition of a business. The allocation was based upon relative fair values. The revenue-sharing income allocated to the U.S. was recognized as collaboration and other revenue, consistent with our policy for royalty revenue, while the income related to the prepayment of Amylin's obligation allocated to the U.S. was recognized as other-net, (income) expense. All income allocated to the business outside the U.S. will be recognized on a pro rata basis as a gain on the disposition of a business in other–net, (income) expense as control of the business transfers to Amylin during 2013. We expect to recognize a net gain of approximately $490 million in 2013 contingent upon the transfer of the commercial rights outside the United States.

Prior to termination of the collaboration, we and Amylin were co-promoting Byetta in the United States. Amylin was responsible for manufacturing and primarily utilized third-party contract manufacturers to supply Byetta. We supplied Byetta pen delivery devices for Amylin and will continue to do so for a period that will not extend beyond December 31, 2013. We are responsible for certain development costs related to certain clinical trials outside the U.S. that we were conducting as of the date of the termination agreement as well as commercialization costs outside the U.S. until the commercial operations are transferred to Amylin.

Under the terms of our prior arrangement, we reported as collaboration and other revenue our 50 percent share of gross margin on Amylin’s net product sales in the United States. We reported as net product sales 100 percent of sales outside the U.S. and our sales of Byetta pen delivery devices to Amylin. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. will continue until those operations transfer to Amylin. Prior to its termination, under the 50/50 profit-sharing arrangement for the U.S., in addition to recording as revenue our 50 percent share of exenatide’s gross margin, we also recorded approximately 50 percent of U.S. related research and development costs and marketing and selling costs in the respective line items on the consolidated statements of operations.

In accordance with the prior arrangement and pursuant to Amylin’s request, we loaned Amylin $165.0 million in the second quarter of 2011. This loan and related accrued interest were also paid in full in August 2012.

The following table summarizes the revenue and other income recognized with respect to exenatide:



	2012		2011		2010
Net product sales	$	207.8	$	179.6	$	168.1
Collaboration and other revenue	70.1		243.1		262.5
Total revenue	$	277.9	$	422.7	$	430.6

Income related to prepayment of Amylin's obligation⁽¹⁾	$	787.8	$	—	$	—

¹ Presented in other-net, (income) expense

Erbitux

We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Japan, and Canada (Bristol-Myers Squibb Company); and worldwide except the U.S. and Canada (Merck KGaA). The agreements are expected to expire in 2018, upon which all of the rights with respect to Erbitux in the U.S. and Canada return to us and certain rights with respect to Erbitux outside the U.S. and Canada (excluding Japan) remain with Merck KGaA (Merck). The following table summarizes the revenue recognized with respect to Erbitux:



	2012		2011		2010
Net product sales	$	76.4	$	87.6	$	71.9
Collaboration and other revenue	320.6		321.6		314.2
Total revenue	$	397.0	$	409.2	$	386.1

Bristol-Myers Squibb Company

Pursuant to a commercial agreement with Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS), relating to Erbitux, we are co-developing Erbitux in the U.S. and Canada with BMS, exclusively, and in Japan with BMS and Merck. The companies have jointly agreed to expand the investment in the ongoing clinical development plan for Erbitux to further explore its use in additional tumor types. Under this arrangement, Erbitux research and development and other costs are shared by both companies according to a predetermined ratio.

Responsibilities associated with clinical and other ongoing studies are apportioned between the parties under the agreement. Collaborative reimbursements received by us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. We receive a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in the U.S. and Canada, which is recorded in collaboration and other revenue. Royalty expense paid to third parties, net of any reimbursements received, is recorded as a reduction of collaboration and other revenue.

We are responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in the territory, and BMS will purchase all of its requirements of API for commercial use from us, subject to certain stipulations per the agreement. Sales of Erbitux to BMS for commercial use are reported in net product sales.

Merck KGaA

A development and license agreement with Merck with respect to Erbitux granted Merck exclusive rights to market Erbitux outside of the U.S. and Canada, and co-exclusive rights with BMS and us in Japan. Merck also has rights to manufacture Erbitux for supply in its territory. We receive a royalty on the sales of Erbitux outside of the U.S. and Canada, which is included in collaboration and other revenue as earned. Collaborative reimbursements received for research and for development; and marketing, selling, and administrative expenses are recorded as a reduction to the respective expense line items on the consolidated statement of operations. Royalty expense paid to third parties, net of any royalty reimbursements received, is recorded as a reduction of collaboration and other revenue.

Necitumumab

The commercial agreement with BMS described above includes the co-development and co-commercialization of necitumumab, which is currently in Phase III clinical testing for squamous non-small cell lung cancer. Under the agreement, we and BMS have shared in the costs of developing and potentially commercializing necitumumab; however, in the fourth quarter of 2012, BMS provided notice of termination of its involvement with necitumumab. Under the terms of the agreement, BMS will continue to fund a portion of the costs over the following 18-month period, at which point BMS's involvement with necitumumab will terminate and we will hold exclusive rights to necitumumab in all markets.

Effient

We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. We and Daiichi Sankyo co-promote Effient in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. Daiichi Sankyo has exclusive marketing rights in Japan and certain other territories. The parties share approximately 50/50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We record product sales in our exclusive and co-promotion territories. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. Profit-share payments made to Daiichi Sankyo are recorded as marketing, selling, and administrative expenses. All royalties paid to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. Effient sales were $457.2 million, $302.5 million, and $115.0 million for the years ended December 31, 2012, 2011, and 2010, respectively.

Diabetes Collaboration

In January 2011, we and Boehringer Ingelheim entered into a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Included are Boehringer Ingelheim's two oral diabetes agents, linagliptin and empagliflozin. Subsequently in 2011, linagliptin was approved and launched in the U.S. (trade name Tradjenta), Japan (trade name Trazenta^TM), Europe (trade name Trajenta^®), and other countries. Empagliflozin is currently in Phase III clinical testing. Also included in the agreement were our new insulin glargine product and our novel basal insulin analog, both of which began Phase III clinical testing in the second half of 2011; and an option granted to Boehringer Ingelheim to co-develop and co-commercialize our anti-TGF-beta monoclonal antibody, which is currently in Phase II clinical testing. Subsequently in 2013, Boehringer Ingelheim elected to terminate our collaboration with respect to the novel basal insulin analog. Under the terms of the global agreement, we made an initial one-time payment to Boehringer Ingelheim of $388.0 million and recorded an acquired IPR&D charge, which was included as expense in the first quarter of 2011 and is deductible for tax purposes.

In connection with the approval of linagliptin in the U.S., Japan, and Europe, in 2011 we paid $478.7 million in success-based regulatory milestones, all of which were capitalized as intangible assets and are being amortized to cost of sales. We may pay up to 300.0 million euro in additional success-based regulatory milestones for empagliflozin. We will be eligible to receive up to a total of $300.0 million in success-based regulatory milestones on our new insulin glargine product. Should Boehringer Ingelheim elect to opt in to the Phase III development and potential commercialization of the anti-TGF-beta monoclonal antibody, we would be eligible for up to $525.0 million in opt-in and success-based regulatory milestone payments. The companies share ongoing development costs equally. The companies also share in the commercialization costs and gross margin for any product resulting from the collaboration that receives regulatory approval. We record our portion of the gross margin as collaboration and other revenue, and we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. Revenue related to this collaboration was not material during the years ended December 31, 2012 and 2011.

Cymbalta

Boehringer Ingelheim

We were in a collaborative arrangement with Boehringer Ingelheim to jointly develop, market, and promote Cymbalta (duloxetine) outside the U.S. and Japan. Pursuant to the terms of the agreement, we generally shared equally in development, marketing, and selling expenses, and paid Boehringer Ingelheim a commission on sales in the co-promotion territories. We manufactured the product for all territories. Reimbursements or payments for the cost sharing of marketing, selling, and administrative expenses were recorded in the respective expense line items in the consolidated statements of operations. The commission paid to Boehringer Ingelheim was recorded in marketing, selling, and administrative expenses. In March 2010, the parties agreed to terminate this agreement, and we reacquired the exclusive rights to develop and market duloxetine for all indications in countries outside the U.S. and Japan. In connection with the termination, we paid Boehringer Ingelheim approximately $400 million and will also pay to Boehringer Ingelheim a percentage of our sales of duloxetine in these countries through the end of 2012 as consideration for the rights acquired. We record these costs as intangible assets that are amortized to marketing, selling, and administrative expenses using the straight-line method over the life of the original agreement, which is through the third quarter of 2015.

Quintiles

We were in a collaborative arrangement with Quintiles Transnational Corp. (Quintiles) to jointly market and promote Cymbalta in the United States. Pursuant to the terms of the agreement, Quintiles shared in the costs to co-promote Cymbalta with us and received a commission based upon net product sales. Quintiles' obligation to promote Cymbalta expired during 2009, and we incurred a lower commission for three years after completion of their promotion efforts. The commissions paid to Quintiles were recorded as marketing, selling, and administrative expenses.

Solanezumab

We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs was not material and ended in the first half of 2011. In exchange for their funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties that are contingent upon the successful development of solanezumab. The royalties relating to solanezumab would be paid for approximately eight years after launch of a product.

Baricitinib

In December 2009, we entered into a worldwide license and collaboration agreement with Incyte Corporation (Incyte) to acquire development and commercialization rights to its JAK inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. The agreement calls for payments of up to $515.0 million associated with certain development and regulatory milestones as well as an additional $150.0 million of potential sales-based milestones. Incyte also has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. The agreement also provides Incyte with an option to co-promote in the United States. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. We made development milestone payments of $49.0 million in 2010 related to Phase II trials of baricitinib. Upon initiation of Phase III trials for the treatment of rheumatoid arthritis in the fourth quarter of 2012, we incurred an additional milestone-related expense of $50.0 million. These milestone payments were recorded as research and development expenses.

Summary of Collaboration-Related Commission and Profit-Share Payments

The aggregate amount of commission and profit-share payments included in marketing, selling, and administrative expense pursuant to the collaborations described above was $261.5 million, $219.2 million, and $174.5 million for the years ended December 31, 2012, 2011, and 2010, respectively.

Asset Impairments, Restructuring, and Other Special Charges

12 Months Ended

Dec. 31, 2012

Other Cost and Expense Disclosure, Operating [Abstract]

Asset Impairments, Restructuring, And Other Special Charges [Text Block]

Note 5: Asset Impairments, Restructuring, and Other Special Charges

The components of the charges included in asset impairments, restructuring, and other special charges in our consolidated statements of operations are described below.



	2012		2011		2010
Severance	$	74.5	$	251.8	$	142.0
Asset impairments and other special charges	206.6		149.6		50.0
Asset impairments, restructuring, and other special charges	$	281.1	$	401.4	$	192.0

Severance costs for all years relate to initiatives to reduce our cost structure and global workforce.

For the year ended December 31, 2012, we incurred $206.6 million of asset impairments and other special charges consisting of $122.6 million related to an intangible asset impairment for liprotamase (see Note 7) net of the reduction of the related contingent consideration liability (see Note 6), $64.0 million related to the recognition of an asset impairment associated with the decision to stop development of a delivery device platform, and $20.0 million resulting from a change in our estimates of returned product related to the withdrawal of Xigris from the market during the fourth quarter of 2011.

For the year ended December 31, 2011, we incurred $149.6 million of asset impairments and other special charges primarily consisting of $85.0 million for returned product and contractual commitments related to the withdrawal of Xigris from the market and $56.1 million related to our decision to vacate certain leased premises, a decision that was as a result of our initiative to reorganize global operations, streamline various functions of the business, and reduce the total number of employees.

For the year ended December 31, 2010, we incurred $50.0 million of asset impairments and other special charges primarily consisting of lease termination costs and asset impairments outside the United States.

Financial Instruments

12 Months Ended

Dec. 31, 2012

Fair Value Disclosures [Abstract]

Financial Instruments [Text Block]

Note 6: Financial Instruments

Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

At December 31, 2012, we had outstanding foreign currency forward commitments to purchase 273.8 million U.S. dollars and sell 210.0 million euro, and commitments to purchase 212.0 million euro and sell 277.4 million U.S. dollars, which will all settle within 45 days.

At December 31, 2012, approximately 100 percent of our total debt is at a fixed rate. We have converted approximately 60 percent of our fixed-rate debt to floating rates through the use of interest rate swaps.

The Effect of Risk Management Instruments on the Statement of Operations

The following effects of risk-management instruments were recognized in other—net, (income) expense:



	2012			2011			2010
Fair value hedges
Effect from hedged fixed-rate debt	$	51.5		$	259.6		$	149.6
Effect from interest rate contracts	(51.5		)	(259.6		)	(149.6		)
Cash flow hedges
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	9.0			9.0			9.0
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	(35.8		)	97.4			12.0

The effective portion of net gains (losses) on equity contracts in designated cash flow hedging relationships recorded in other comprehensive income (loss) was $0.0 million, $35.6 million, and $(35.6) million for the years ended December 31, 2012, 2011, and 2010, respectively. There have been no equity contracts in designated cash flow hedging relationships in 2012.

During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $9.0 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt.

During the years ended December 31, 2012, 2011, and 2010, net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material.

Fair Value of Financial Instruments

The following tables summarize certain fair value information at December 31 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments:



					Fair Value Measurements Using
Description	Carrying Amount		Amortized Cost		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)	Fair Value
December 31, 2012
Cash and cash equivalents	$	4,018.8	$	4,018.8	$	3,964.4	$	54.4	$	$	4,018.8
Short-term investments
U.S. government and agencies	$	150.2	$	150.2	$	150.2	$		$	$	150.2
Corporate debt securities	1,503.5		1,501.5				1,503.5			1,503.5
Other securities	11.8		11.8				11.8			11.8
Short-term investments	$	1,665.5	$	1,663.5
Noncurrent investments
U.S. government and agencies	$	1,362.7	$	1,360.3	$	1,122.4	$	240.3	$	$	1,362.7
Corporate debt securities	3,351.3		3,322.9				3,351.3			3,351.3
Mortgage-backed	668.1		677.7				668.1			668.1
Asset-backed	519.0		523.5				519.0			519.0
Other securities	3.3		3.3				3.3			3.3
Marketable equity	175.8		83.0		175.8					175.8
Equity method and other investments⁽¹⁾	233.1		233.1
Noncurrent investments	$	6,313.3	$	6,203.8

December 31, 2011
Cash and cash equivalents	$	5,922.5	$	5,922.5	$	5,264.6	$	657.9	$	$	5,922.5
Short-term investments
U.S. government and agencies	$	362.3	$	362.3	$	351.3	$	11.0	$	$	362.3
Corporate debt securities	600.7		601.1				600.7			600.7
Other securities	11.6		11.6				11.6			11.6
Short-term investments	$	974.6	$	975.0
Noncurrent investments
U.S. government and agencies	$	908.8	$	901.3	$	673.5	$	235.3	$	$	908.8
Corporate debt securities	2,081.3		2,093.3				2,081.3			2,081.3
Mortgage-backed	443.8		479.1				443.8			443.8
Asset-backed	245.0		253.2				245.0			245.0
Other securities	10.0		11.9				8.7		1.3	10.0
Marketable equity	180.8		107.5		180.8					180.8
Equity method and other investments⁽¹⁾	160.1		160.1
Noncurrent investments	$	4,029.8	$	4,006.4


¹	Fair value not applicable



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
Long-term debt, including current portion
December 31, 2012	$	(5,531.3	)	$	$	(5,996.6	)	$	$	(5,996.6	)
December 31, 2011	(6,981.5		)		(7,451.5		)		(7,451.5		)



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
December 31, 2012
Risk-management instruments
Interest rate contracts designated as hedging instruments
Sundry	$	589.4		$	$	589.4		$	$	589.4
Foreign exchange contracts not designated as hedging instruments
Other receivables	11.0				11.0				11.0
Other current liabilities	(17.5		)		(17.5		)		(17.5		)

December 31, 2011
Risk-management instruments
Interest rate contracts designated as hedging instruments
Other receivables	$	6.1		$	$	6.1		$	$	6.1
Sundry	531.7				531.7				531.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	16.2				16.2				16.2
Other current liabilities	(25.9		)		(25.9		)		(25.9		)

The fair value of the contingent consideration liability related to prior acquisitions, a Level 3 measurement in the fair value hierarchy, was $0.0 million and $121.6 million as of December 31, 2012 and 2011, respectively. The decrease in the fair value of the contingent consideration to zero as of December 31, 2012 was due to our expectations for the applicable products (see Note 5) and a $50.0 million approval milestone that was paid for Amyvid in the second quarter of 2012.

We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available.

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2012:



	Maturities by Period
	Total		Less Than 1 Year		1-5 Years		6-10 Years		More Than 10 Years
Fair value of debt securities	$	7,569.9	$	1,665.5	$	4,776.5	$	373.9	$	754.0

A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows:



	2012		2011
Unrealized gross gains	$	140.5	$	103.0
Unrealized gross losses	29.0		80.0
Fair value of securities in an unrealized gain position	5,246.0		2,498.9
Fair value of securities in an unrealized loss position	2,102.0		2,164.4

Other-than-temporary impairment losses on fixed income securities of $12.2 million, $26.8 million, and $12.0 million were recognized in the consolidated statements of operations for the years ended December 31, 2012, 2011, and 2010, respectively. The amount of credit losses represents the difference between the present value of cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing the credit loss were the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration.

The securities in an unrealized loss position include fixed-rate debt securities of varying maturities. The value of fixed income securities is sensitive to changes in the yield curve and other market conditions. Approximately 90 percent of the securities in a loss position are investment-grade debt securities. At this time, there is no indication of default on interest or principal payments for debt securities other than those for which an other-than-temporary impairment charge has been recorded. We do not intend to sell and it is not more likely than not we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and we have concluded that no additional other-than-temporary loss is required to be charged to earnings as of December 31, 2012.

Activity related to our available-for-sale investment portfolio was as follows:



	2012		2011		2010
Proceeds from sales	$	6,529.8	$	2,268.3	$	760.3
Realized gross gains on sales	82.3		140.0		110.7
Realized gross losses on sales	10.9		9.9		4.8

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Goodwill and Other Intangibles

12 Months Ended

Dec. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Note 7: Goodwill and Other Intangibles

Goodwill and other indefinite-lived intangible assets at December 31 were as follows:



	2012		2011
Indefinite-lived intangible assets
Goodwill	$	1,501.3	$	1,434.7
In-process research and development	65.0		474.9
Total indefinite-lived intangible assets	$	1,566.3	$	1,909.6

Substantially all of our goodwill balance is attributable to the human pharmaceutical business segment. No impairments occurred with respect to the carrying value of goodwill for the years ended December 31, 2012, 2011, or 2010.

IPR&D consists of the acquisition date fair value of products under development acquired in business combinations that have not yet achieved regulatory approval for marketing adjusted for subsequent impairments. As discussed in Note 1, we use the "income method" to calculate the fair value of the IPR&D assets, which is a Level 3 fair value measurement.

In 2012, we recorded impairment charges of $205.0 million related to liprotamase as a result of changes in key assumptions used in the valuation, based upon additional communications with the FDA regarding the clinical trial that would be required for resubmission, and our expectations for the product. The remaining reduction of IPR&D in 2012 was primarily due to the reclassification of the $190.0 million Amyvid intangible asset from indefinite to finite-lived upon receiving FDA approval for marketing.

In 2011, we recorded impairment charges of $151.5 million due primarily to the impairment of the IPR&D assets related to Amyvid and liprotamase. The impairment of Amyvid was due to a delay in product launch and lower sales projections during the early part of the product’s expected life cycle. In April 2011, we received a complete response letter from the FDA for the NDA for liprotamase, which communicated the need for us to conduct an additional clinical trial prior to a resubmission, resulting in an impairment of liprotamase. No material impairments occurred with respect to the carrying value of indefinite-lived intangible assets for the year ended December 31, 2010.

The components of finite-lived intangible assets at December 31 were as follows:



	2012							2011
Description	Carrying Amount— Gross		Accumulated Amortization			Carrying Amount— Net		Carrying Amount— Gross		Accumulated Amortization			Carrying Amount— Net
Finite-lived intangible assets
Marketed products	$	5,107.9	$	(1,987.0	)	$	3,120.9	$	4,624.9	$	(1,481.2	)	$	3,143.7
Other	129.5		(64.0		)	65.5		117.3		(42.5		)	74.8
Total finite-lived intangible assets	$	5,237.4	$	(2,051.0	)	$	3,186.4	$	4,742.2	$	(1,523.7	)	$	3,218.5

Marketed products consist of the amortized cost of the rights to assets acquired in business combinations and approved for marketing in a significant global jurisdiction (U.S., Europe, and Japan) and capitalized milestone payments. Other intangibles consist primarily of the amortized cost of licensed platform technologies that have alternative future uses in research and development, manufacturing technologies, and customer relationships from business combinations. No material impairments occurred with respect to the carrying value of finite-lived intangible assets for the years ended December 31, 2012, 2011 and 2010.

See Note 3 for further discussion of intangible assets acquired in recent business combinations.

As of December 31, 2012, the remaining weighted-average amortization period for finite-lived intangible assets is approximately 9 years. Amortization expense was $563.0 million, $469.0 million, and $385.7 million for 2012, 2011, and 2010, respectively. The estimated amortization expense associated with our current finite-lived intangible assets for each of the next five years approximates $540 million in 2013, $530 million in 2014, $480 million in 2015, $380 million in 2016, and $200 million in 2017. Amortization expense is included in either cost of sales, marketing, selling, and administrative or research and development depending on the nature of the intangible asset being amortized.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Borrowings

12 Months Ended

Dec. 31, 2012

Long-term Debt, Current and Noncurrent [Abstract]

Debt Disclosure [Text Block]

Note 8: Borrowings

Long-term debt at December 31 consisted of the following:



	2012			2011
3.55 to 7.13 percent notes (due 2012-2037)	$	4,887.3		$	6,387.4
Other, including capitalized leases	37.4			37.6
Fair value adjustment	606.6			556.5
	5,531.3			6,981.5
Less current portion	(11.9		)	(1,516.8		)
Long-term debt	$	5,519.4		$	5,464.7

Current maturities of long-term debt of $1.50 billion were repaid during the year ended December 31, 2012.

The 6.55 percent Employee Stock Ownership Plan (ESOP) debentures of $63.7 million were repaid in full during the year ended December 31, 2011.

The aggregate amounts of maturities on long-term debt for the next five years are $11.9 million in 2013, $1.01 billion in 2014, $9.0 million in 2015, $203.9 million in 2016, and $1.00 billion in 2017.

At December 31, 2012 and 2011, short-term borrowings included $0.0 million and $5.5 million, respectively, of notes payable to banks. At December 31, 2012, we have $1.36 billion of unused committed bank credit facilities, $1.20 billion of which is a revolving credit facility that backs our commercial paper program and matures in April 2015. There were no amounts outstanding under the revolving credit facility during the year ended December 31, 2012. Compensating balances and commitment fees are not material, and there are no conditions that are probable of occurring under which the lines may be withdrawn.

In 2010, we borrowed $125.0 million of short-term floating-rate debt, which was repaid in full during the year ended December 31, 2011.

We have converted approximately 60 percent of all fixed-rate debt to floating rates through the use of interest rate swaps. The weighted-average effective borrowing rates based on debt obligations and interest rates at December 31, 2012 and 2011, including the effects of interest rate swaps for hedged debt obligations, were 3.20 percent and 3.00 percent, respectively.

For the years ended December 31, 2012, 2011, and 2010, cash payments for interest on borrowings totaled $171.9 million, $167.4 million, and $176.3 million, respectively, net of capitalized interest.

In accordance with the requirements of derivatives and hedging guidance, the portion of our fixed-rate debt obligations that is hedged, as a fair value hedge, is reflected in the consolidated balance sheets as an amount equal to the sum of the debt’s carrying value plus the fair value adjustment representing changes in fair value of the hedged debt attributable to movements in market interest rates subsequent to the inception of the hedge.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2012

Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]

Stock-Based Compensation [Text Block]

Note 9: Stock-Based Compensation

Stock-based compensation expense in the amount of $141.5 million, $147.4 million, and $231.0 million was recognized for the years ended December 31, 2012, 2011, and 2010, respectively, as well as related tax benefits of $49.5 million, $51.6 million, and $80.8 million, respectively. Our stock-based compensation expense consists primarily of performance awards (PAs), shareholder value awards (SVAs), and restricted stock units (RSUs). We recognize the stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. We provide newly issued shares and treasury stock to satisfy stock option exercises and for the issuance of PA, SVA, and RSU shares. We classify tax benefits resulting from tax deductions in excess of the compensation cost recognized for exercised stock options as a financing cash flow in the consolidated statements of cash flows.

At December 31, 2012, additional stock-based compensation awards may be granted under the 2002 Lilly Stock Plan for not more than 92.0 million shares.

Performance Award Program

PAs are granted to officers and management and are payable in shares of our common stock. The number of PA shares actually issued, if any, varies depending on the achievement of certain pre-established earnings-per-share targets over a two-year period. PA shares are accounted for at fair value based upon the closing stock price on the date of grant and fully vest at the end of the measurement periods. The fair values of PAs granted for the years ended December 31, 2012, 2011, and 2010 were $35.74, $31.90, and $30.88, respectively. The number of shares ultimately issued for the PA program is dependent upon the earnings achieved during the vesting period. Pursuant to this plan, approximately 1.6 million shares, 3.9 million shares, and 3.8 million shares were issued during the years ended December 31, 2012, 2011, and 2010, respectively. Approximately 0.7 million shares are expected to be issued in 2013. As of December 31, 2012, the total remaining unrecognized compensation cost related to nonvested PAs amounted to $17.2 million, which will be amortized over the weighted-average remaining requisite service period of 12 months.

Shareholder Value Award Program

SVAs are granted to officers and management and are payable in shares of common stock at the end of a three-year period. The number of shares actually issued varies depending on our stock price at the end of the three-year vesting period compared to pre-established target stock prices. We measure the fair value of the SVA unit on the grant date using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables that determine the probability of satisfying the market condition stipulated in the award grant and calculates the fair value of the award. Expected volatilities utilized in the model are based on implied volatilities from traded options on our stock, historical volatility of our stock price, and other factors. Similarly, the dividend yield is based on historical experience and our estimate of future dividend yields. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The weighted-average fair values of the SVA units granted during the years ended December 31, 2012, 2011, and 2010 were $30.35, $28.33, and $25.97, respectively, determined using the following assumptions:



(Percents)	2012	2011	2010
Expected dividend yield	4.50	4.90	4.50
Risk-free interest rate	.10-.36	.20-1.36	.10-1.36
Range of volatilities	22.40-25.64	27.61-29.10	28.00-28.69

A summary of the SVA activity is presented below:



	Units Attributable to SVAs (in thousands)
Outstanding at January 1, 2010	2,760
Granted	1,987
Issued	(365	)
Forfeited or expired	(745	)
December 31, 2010	3,637
Granted	1,830
Issued	(428	)
Forfeited or expired	(740	)
December 31, 2011	4,299
Granted	1,742
Issued	(973	)
Forfeited or expired	(165	)
December 31, 2012	4,903

The maximum number of shares that could ultimately be issued upon vesting of the SVA units outstanding at December 31, 2012, is 6.9 million. Approximately 2.4 million shares are expected to be issued in 2013. As of December 31, 2012, the total remaining unrecognized compensation cost related to nonvested SVAs amounted to $48.2 million, which will be amortized over the weighted-average remaining requisite service period of 20 months.

Restricted Stock Units

RSUs are granted to certain employees and are payable in shares of our common stock. RSU shares are accounted for at fair value based upon the closing stock price on the date of grant. The corresponding expense is amortized over the vesting period, typically 3 years. The fair values of RSU awards granted during the years ended December 31, 2012, 2011, and 2010 were $39.65, $35.80, and $34.78, respectively. The number of shares ultimately issued for the RSU program remains constant with the exception of forfeitures. Pursuant to this plan, 1.4 million, 1.5 million, and 1.5 million shares were granted during the years ended December 31, 2012, 2011, and 2010, respectively, and approximately 0.3 million, 0.2 million, and 0.2 million shares were issued during the years ended December 31, 2012, 2011, and 2010, respectively. Approximately 0.9 million shares are expected to be issued in 2013. As of December 31, 2012, the total remaining unrecognized compensation cost related to nonvested RSUs amounted to $54.6 million, which will be amortized over the weighted-average remaining requisite service period of 21 months.

Stock Option Program

Stock options were granted prior to 2007 to officers, management, and board members at exercise prices equal to the fair market value of our stock price at the date of grant. Options fully vested 3 years from the grant date and have a term of 10 years.

Stock option activity during the year ended December 31, 2012 is summarized below:



	Shares of Common Stock Attributable to Options (in thousands)		Weighted-Average Exercise Price of Options		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2012	36,556		$	66.22
Exercised	(50	)	20.37
Forfeited or expired	(9,274	)	73.28
Outstanding at December 31, 2012	27,232		63.89		1.2	$	0.4
Exercisable at December 31, 2012	27,232		63.89		1.2	0.4

For options exercised during the years ended December 31, 2012, 2011, and 2010, the related intrinsic value, cash received, and tax benefits were not material.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Other Assets and Other Liabilities	12 Months Ended
Other Assets and Other Liabilities	Dec. 31, 2012
Other Assets and Other Liabilities [Abstract]
Other Assets and Other Liabilities [Text Block]	Note 10: Other Assets and Other Liabilities Other receivables include tax receivables, receivables from our collaboration partners, interest receivable on the interest rate swaps, and a variety of other items. Prepaid expenses and other includes global prepaid operating expenses and deferred taxes (Note 13). Sundry assets primarily include deferred tax assets (Note 13), the fair value of interest rate swaps, capitalized computer software, and prepaid retirement plan outside the United States. Other current liabilities include deferred income from our collaboration arrangements, other taxes payable, the current portion of our estimated product return liabilities, and a variety of other items. Other noncurrent liabilities include deferred income from our collaboration and out-licensing arrangements, the long-term portion of our estimated product return liabilities, deferred tax liabilities (Note 13), product litigation, and a variety of other items.

Shareholders' Equity

12 Months Ended

Dec. 31, 2012

Stockholders' Equity Note [Abstract]

Shareholders' Equity [Text Block]

Note 11: Shareholders' Equity

Changes in certain components of shareholders' equity were as follows:



	Additional Paid-in Capital			Retained Earnings			Deferred Costs - ESOP			Common Stock in Treasury
										Shares (in thousands)		Amount
Balance at January 1, 2010	$	4,635.6		$	9,830.4		$	(77.4	)	882		$	98.5
Net income				5,069.5
Cash dividends declared per share: $1.96				(2,167.3		)
Retirement of treasury shares	(1.0		)							(28	)	(1.0		)
Issuance of stock under employee stock plans-net	(87.6		)							10		(1.1		)
Stock-based compensation	231.0
ESOP transactions	20.5						25.0
Balance at December 31, 2010	4,798.5			12,732.6			(52.4		)	864		96.4
Net income				4,347.7
Cash dividends declared per share: $1.96				(2,182.5		)
Retirement of treasury shares	(0.1		)							(1	)	(0.1		)
Issuance of stock under employee stock plans-net	(108.7		)							(10	)	(1.0		)
Stock-based compensation	147.4
ESOP transactions	49.7						52.4
Balance at December 31, 2011	4,886.8			14,897.8			—			853		95.3
Net income				4,088.6
Cash dividends declared per share: $1.96				(2,186.5		)
Retirement of treasury shares				(711.7		)				(14,912	)	(721.1		)
Purchase for treasury										16,918		819.2
Issuance of stock under employee stock plans-net	(65.2		)							(9	)	(1.0		)
Stock-based compensation	141.5
Balance at December 31, 2012	$	4,963.1		$	16,088.2		$	—		2,850		$	192.4

During 2012, we repurchased $819.2 million of shares, including $419.2 million remaining under the $3.00 billion share repurchase program announced in 2000 and $400.0 million under the $1.50 billion program announced in 2012. No shares were repurchased during the years ended December 31, 2011 and 2010.

We have 5 million authorized shares of preferred stock. As of December 31, 2012 and 2011, no preferred stock has been issued.

We have an employee benefit trust that held 50.0 million and 50.0 million shares of our common stock at December 31, 2012 and 2011, respectively, to provide a source of funds to assist us in meeting our obligations under various employee benefit plans. The cost basis of the shares held in the trust was $3.01 billion and $3.01 billion at December 31, 2012 and 2011, respectively, and is shown as a reduction in shareholders’ equity. Any dividend transactions between us and the trust are eliminated. Stock held by the trust is not considered outstanding in the computation of earnings per share. The assets of the trust were not used to fund any of our obligations under these employee benefit plans during the years ended December 31, 2012, 2011, and 2010.

We have an ESOP as a funding vehicle for the existing employee savings plan. The ESOP used the proceeds of a loan from us to purchase shares of common stock from the treasury. The ESOP issued third-party debt, which was repaid in 2011 (Note 8). The proceeds were used to purchase shares of our common stock on the open market. As of December 31, 2012, all shares of common stock held by the ESOP were allocated to participating employees as part of our savings plan contribution. The fair value of shares allocated each period was recognized as compensation expense.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Earnings Per Share

12 Months Ended

Dec. 31, 2012

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 12: Earnings Per Share

Following is a reconciliation of the denominators used in computing earnings per share:



	2012		2011		2010
	(Shares in thousands)
Income available to common shareholders	$	4,088.6	$	4,347.7	$	5,069.5
Basic earnings per share
Weighted-average number of common shares outstanding, including incremental shares	1,113,178		1,113,923		1,105,788
Basic earnings per share	$	3.67	$	3.90	$	4.58
Diluted earnings per share
Weighted-average number of common shares outstanding, including incremental shares and stock options	1,117,294		1,113,967		1,105,813
Diluted earnings per share	$	3.66	$	3.90	$	4.58

Income Taxes

12 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Abstract]

Income Taxes [Text Block]

Note 13: Income Taxes

Following is the composition of income tax expense:



	2012		2011			2010
Current
Federal	$	596.8	$	671.4		$	376.2
Foreign	540.6		759.5			513.9
State	56.2		(22.9		)	23.3
Total current tax expense	1,193.6		1,408.0			913.4
Deferred
Federal	87.0		(398.5		)	624.4
Foreign	29.9		(34.7		)	(55.2		)
State	9.1		27.0			(26.9		)
Total deferred tax expense (benefit)	126.0		(406.2		)	542.3
Income taxes	$	1,319.6	$	1,001.8		$	1,455.7

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2012			2011
Deferred tax assets
Compensation and benefits	$	1,081.8		$	1,286.5
Tax credit carryforwards and carrybacks	703.2			695.3
Tax loss carryforwards and carrybacks	370.1			406.1
Asset purchases	366.8			386.2
Sale of intangibles	278.6			207.1
Debt	232.8			214.9
Intercompany profit in inventories	159.6			277.2
Product return reserves	153.8			146.2
Contingencies	113.2			94.5
Other	361.5			292.8
Total gross deferred tax assets	3,821.4			4,006.8
Valuation allowances	(675.8		)	(611.9		)
Total deferred tax assets	3,145.6			3,394.9
Deferred tax liabilities
Unremitted earnings	(920.4		)	(940.2		)
Intangibles	(708.8		)	(797.6		)
Inventories	(573.4		)	(489.2		)
Property and equipment	(407.1		)	(451.0		)
Financial instruments	(257.0		)	(196.9		)
Total deferred tax liabilities	(2,866.7		)	(2,874.9		)
Deferred tax assets - net	$	278.9		$	520.0

At December 31, 2012 and 2011, no individually significant items were classified as “Other” deferred tax assets.

The deferred tax asset and related valuation allowance amounts for U.S. federal and state net operating losses and tax credits shown above have been reduced for differences between financial reporting and tax return filings.

Based on filed tax returns, we have tax credit carryforwards and carrybacks of $973.2 million available to reduce future income taxes; $433.4 million will be carried back; $0.7 million of the tax credit carryforwards will expire between 10 and 20 years; and $3.7 million of the tax credit carryforwards will never expire. The remaining portion of the tax credit carryforwards is related to federal tax credits of $80.3 million, international tax credits of $93.6 million, and state tax credits of $361.5 million, all of which are substantially reserved.

At December 31, 2012, based on filed tax returns we had net operating losses and other carryforwards for international and U.S. income tax purposes of $737.5 million: $309.7 million will expire within 5 years; $394.5 million will expire between 5 and 20 years; and $33.4 million of the carryforwards will never expire. Deferred tax assets related to state net operating losses of $100.7 million and $16.4 million of other state carryforwards are substantially reserved.

Domestic and Puerto Rican companies contributed approximately 54 percent, 24 percent, and 45 percent for the years ended December 31, 2012, 2011, and 2010, respectively, to consolidated income before income taxes. We have a subsidiary operating in Puerto Rico under a tax incentive grant. The current tax incentive grant will not expire prior to 2017.

At December 31, 2012, we had an aggregate of $20.98 billion of unremitted earnings of foreign subsidiaries that have been or are intended to be permanently reinvested for continued use in foreign operations and that, if distributed, would result in additional income tax expense at approximately the U.S. statutory rate.

Cash payments of income taxes totaled $992.0 million, $943.0 million, and $861.0 million, for the years ended December 31, 2012, 2011, and 2010, respectively.

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2012			2011			2010
Income tax at the U.S. federal statutory tax rate	$	1,892.9		$	1,872.3		$	2,283.8
Add (deduct)
International operations, including Puerto Rico	(593.8		)	(796.7		)	(823.3		)
U.S. health care reform	59.8			62.9			85.1
General business credits	(11.2		)	(80.8		)	(83.2		)
IRS audit conclusion	—			(85.3		)	—
Other	(28.1		)	29.4			(6.7		)
Income taxes	$	1,319.6		$	1,001.8		$	1,455.7

The American Taxpayer Relief Act of 2012, which included the reinstatement of the research tax credit for the year 2012, was enacted in early 2013. While we expect to claim a research tax credit for 2012, we are required to record the tax benefit, which is presented with other general business credits, in the year it is enacted.

In October 2010, Puerto Rico enacted excise tax legislation that affected our operations beginning with the year ended December 31, 2011. The excise tax is imposed on the purchase of goods and services from a related manufacturer in Puerto Rico, and is therefore included in costs of sales in our consolidated statement of operations rather than income taxes. The Internal Revenue Service (IRS) has stated it would not challenge a taxpayer’s position that this excise tax is creditable for U.S. income tax purposes, pending the resolution of numerous legal and factual issues. As a result, the benefit in 2012 and 2011 on international operations reported in the effective tax rate reconciliation above includes the foreign tax credit related to the excise tax.

The U.S. health care legislation (both the primary Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act) eliminated the tax-free nature of the subsidy we receive for sponsoring retiree drug coverage that is “actuarially equivalent” to Medicare Part D. This provision is effective January 1, 2013. While this change has a future impact on our net tax deductions related to retiree health benefits, we were required to record a one-time charge to adjust our deferred tax asset for this change in the law in the quarter of enactment. Accordingly, we recorded a non-cash charge of $85.1 million in the first quarter of 2010. In addition, U.S. health care reform mandated an annual industry fee effective beginning January 1, 2011, which is not deductible for tax purposes.

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2012			2011			2010
Beginning balance at January 1	$	1,274.8		$	1,619.6		$	1,351.2
Additions based on tax positions related to the current year	141.5			89.4			186.2
Additions for tax positions of prior years	70.1			390.0			117.0
Reductions for tax positions of prior years	(38.5		)	(492.3		)	(30.2		)
Settlements	(9.2		)	(326.3		)	(0.1		)
Lapses of statutes of limitation	(4.6		)	(2.6		)	(7.0		)
Changes related to the impact of foreign currency translation	(0.3		)	(3.0		)	2.5
Balance at December 31	$	1,433.8		$	1,274.8		$	1,619.6

The total amount of unrecognized tax benefits that, if recognized, would affect our effective tax rate was $928.1 million and $812.3 million at December 31, 2012 and 2011, respectively.

We file income tax returns in the U.S. federal jurisdiction and various state, local, and non-U.S. jurisdictions. We are no longer subject to U.S. federal, state and local, or non-U.S. income tax examinations in major taxing jurisdictions for years before 2007.

During 2011, we settled the U.S. examinations of tax years 2005-2007, along with certain matters related to tax years 2008-2009. The examination of the remainder of 2008-2009 commenced in the fourth quarter of 2011. Considering this current examination cycle, as well as the settlement of 2005-2007 and certain matters related to 2008-2009, our consolidated results of operations benefited from a reduction in tax expense of $85.3 million in 2011. We made cash payments totaling approximately $300 million for tax years 2005-2007.

The U.S. examination of certain matters related to tax years 2008-2009 that were not settled as part of previous examinations remains in progress. Management believes it is reasonably possible the remaining 2008-2009 tax matters could be concluded within the next 12 months. However, resolution of these matters is still dependent upon a number of factors, including the potential for formal administrative and legal proceedings. As a result, it is not possible to estimate the range of the reasonably possible changes in unrecognized tax benefits that could occur within the next 12 months related to these years, nor is it possible to estimate reliably the total future cash flows related to these unrecognized tax benefits.

We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2012, 2011, and 2010, we recognized income tax expense (benefit) of $42.3 million, $(47.3) million, and $38.3 million, respectively, related to interest and penalties. At December 31, 2012 and 2011, our accruals for the payment of interest and penalties totaled $187.5 million and $134.6 million, respectively. Substantially all of the expense (benefit) and accruals relate to interest.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Retirement Benefits

12 Months Ended

Dec. 31, 2012

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]

Retirement Benefits [Text Block]

Note 14: Retirement Benefits

We use a measurement date of December 31 to develop the change in benefit obligation, change in plan assets, funded status, and amounts recognized in the consolidated balance sheets at December 31 for our defined benefit pension and retiree health benefit plans, which were as follows:



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	2012			2011			2012			2011
Change in benefit obligation
Benefit obligation at beginning of year	$	9,191.2		$	8,115.0		$	2,308.6		$	2,088.5
Service cost	253.1			236.3			63.3			72.4
Interest cost	455.1			447.9			114.9			118.0
Actuarial (gain) loss	834.0			794.7			(57.0		)	110.2
Benefits paid	(404.2		)	(400.1		)	(67.2		)	(77.9		)
Plan amendments	(0.6		)	10.0			(28.4		)	1.1
Foreign currency exchange rate changes and other adjustments	95.2			(12.6		)	3.5			(3.7		)
Benefit obligation at end of year	10,423.8			9,191.2			2,337.7			2,308.6



Change in plan assets
Fair value of plan assets at beginning of year	7,186.3		6,983.0		1,339.0		1,327.7
Actual return on plan assets	922.7		209.2		183.4		16.6
Employer contribution	469.7		402.4		62.8		72.6
Benefits paid	(404.2	)	(400.1	)	(67.2	)	(77.9	)
Foreign currency exchange rate changes and other adjustments	112.1		(8.2	)	—		—
Fair value of plan assets at end of year	8,286.6		7,186.3		1,518.0		1,339.0



Funded status	(2,137.2		)	(2,004.9		)	(819.7		)	(969.6		)
Unrecognized net actuarial loss	5,187.5			4,857.5			1,156.7			1,367.4
Unrecognized prior service (benefit) cost	54.9			57.3			(203.4		)	(215.1		)
Net amount recognized	$	3,105.2		$	2,909.9		$	133.6		$	182.7



Amounts recognized in the consolidated balance sheet consisted of:
Prepaid expenses and other	$	125.5		$	160.8		$	—		$	—
Other current liabilities	(61.2		)	(57.5		)	(8.9		)	(9.3		)
Accrued retirement benefit	(2,201.6		)	(2,108.2		)	(810.8		)	(960.3		)
Accumulated other comprehensive loss before income taxes	5,242.5			4,914.8			953.3			1,152.3
Net amount recognized	$	3,105.2		$	2,909.9		$	133.6		$	182.7

The unrecognized net actuarial loss and unrecognized prior service cost (benefit) have not yet been recognized in net periodic pension costs and are included in accumulated other comprehensive loss at December 31, 2012.

For the year ended December 31, 2013, we expect to recognize from accumulated other comprehensive loss as components of net periodic benefit cost, $395.4 million of unrecognized net actuarial loss and $3.1 million of unrecognized prior service cost related to our defined benefit pension plans, and $96.2 million of unrecognized net actuarial loss and $29.3 million of unrecognized prior service benefit related to our retiree health benefit plans. We do not expect any plan assets to be returned to us in 2013.

The following represents our weighted-average assumptions as of December 31:



	Defined Benefit Pension Plans			Retiree Health Benefit Plans
(Percents)	2012	2011	2010	2012	2011	2010
Weighted-average assumptions as of December 31
Discount rate for benefit obligation	4.3	5.0	5.6	4.3	5.1	5.8
Discount rate for net benefit costs	5.0	5.6	5.9	5.1	5.8	6.0
Rate of compensation increase for benefit obligation	3.4	3.7	3.7
Rate of compensation increase for net benefit costs	3.7	3.7	3.7
Expected return on plan assets for net benefit costs	8.4	8.5	8.8	8.8	8.8	9.0

We annually evaluate the expected return on plan assets in our defined benefit pension and retiree health benefit plans. In evaluating the expected rate of return, we consider many factors, with a primary analysis of current and projected market conditions; asset returns and asset allocations; and the views of leading financial advisers and economists. We may also review our historical assumptions compared with actual results, as well as the assumptions and trend rates utilized by similar plans, where applicable. Health-care-cost trend rates are assumed to increase at an annual rate of 7.1 percent for the year ended December 31, 2013, decreasing by approximately 0.3 percent per year to an ultimate rate of 5.0 percent by 2020.

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:



	2013			2014			2015			2016			2017			2018-2022
Defined benefit pension plans	$	427.1		$	434.0		$	445.3		$	459.1		$	473.8		$	2,646.0

Retiree health benefit plans-gross	$	111.6		$	114.5		$	119.4		$	124.6		$	129.9		$	729.7
Medicare rebates	(6.3		)	(9.5		)	(10.2		)	(10.6		)	(10.9		)	(49.5		)
Retiree health benefit plans-net	$	105.3		$	105.0		$	109.2		$	114.0		$	119.0		$	680.2

The total accumulated benefit obligation for our defined benefit pension plans was $9.46 billion and $8.20 billion at December 31, 2012 and 2011, respectively. The projected benefit obligation and fair value of the plan assets for the defined benefit pension plans with projected benefit obligations in excess of plan assets were $9.15 billion and $6.89 billion, respectively, as of December 31, 2012, and $8.12 billion and $5.96 billion, respectively, as of December 31, 2011. The accumulated benefit obligation and fair value of the plan assets for the defined benefit pension plans with accumulated benefit obligations in excess of plan assets were $8.02 billion and $6.58 billion, respectively, as of December 31, 2012, and $7.03 billion and $5.75 billion, respectively, as of December 31, 2011.

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2012			2011			2010			2012			2011			2010
Components of net periodic benefit cost
Service cost	$	253.1		$	236.3		$	219.2		$	63.3		$	72.4		$	56.5
Interest cost	455.1			447.9			431.6			114.9			118.0			121.4
Expected return on plan assets	(684.8		)	(685.9		)	(638.2		)	(127.2		)	(129.4		)	(122.6		)
Amortization of prior service (benefit) cost	4.2			8.6			8.8			(39.8		)	(42.9		)	(37.2		)
Recognized actuarial loss	285.7			200.4			163.0			98.4			88.7			85.0
Net periodic benefit cost	$	313.3		$	207.3		$	184.4		$	109.6		$	106.8		$	103.1

If the health-care-cost trend rates were to be increased by one percentage point, the December 31, 2012, accumulated postretirement benefit obligation would increase by $218.2 million and the aggregate of the service cost and interest cost components of the 2012 annual expense would increase by $15.6 million. A one percentage point decrease in these rates would decrease the December 31, 2012, accumulated postretirement benefit obligation by $193.6 million, and the aggregate of the 2012 service cost and interest cost by $12.6 million.

The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2012:



	Defined Benefit Pension Plans			Retiree Health Benefit Plans
Actuarial (gain) loss arising during period	$	598.9		$	(113.2	)
Plan amendments during period	(0.6		)	(28.4		)
Amortization of prior service (benefit) cost included in net income	(4.2		)	39.8
Amortization of net actuarial loss included in net income	(285.7		)	(98.4		)
Foreign currency exchange rate changes	19.3			1.1
Total other comprehensive (income) loss during period	$	327.7		$	(199.1	)

We have defined contribution savings plans that cover our eligible employees worldwide. The purpose of these defined contribution plans is generally to provide additional financial security during retirement by providing employees with an incentive to save. Our contributions to the plan are based on employee contributions and the level of our match. Expenses under the plans totaled $127.3 million, $117.6 million, and $119.8 million for the years ended December 31, 2012, 2011, and 2010, respectively.

We provide certain other postemployment benefits primarily related to disability benefits and accrue for the related cost over the service lives of employees. Expenses associated with these benefit plans for the years ended December 31, 2012, 2011, and 2010 were not material.

Benefit Plan Investments

Our benefit plan investment policies are set with specific consideration of return and risk requirements in relationship to the respective liabilities. U.S. and Puerto Rico plans represent 81 percent of our global investments. Given the long-term nature of our liabilities, these plans have the flexibility to manage an above-average degree of risk in the asset portfolios. At the investment-policy level, there are no specifically prohibited investments. However, within individual investment manager mandates, restrictions and limitations are contractually set to align with our investment objectives, ensure risk control, and limit concentrations.

We manage our portfolio to minimize any concentration of risk by allocating funds within asset categories. In addition, within a category we use different managers with various management objectives to eliminate any significant concentration of risk.

Our global benefit plans may enter into contractual arrangements (derivatives) to implement the local investment policy or manage particular portfolio risks. Derivatives are principally used to increase or decrease exposure to a particular public equity, fixed income, commodity, or currency market more rapidly or less expensively than could be accomplished through the use of the cash markets. The plans utilize both exchange-traded and over-the-counter instruments. The maximum exposure to either a market or counterparty credit loss is limited to the carrying value of the receivable, and is managed within contractual limits. We expect all of our counterparties to meet their obligations. The gross values of these derivative receivables and payables are not material to the global asset portfolio, and their values are reflected within the tables below.

The defined benefit pension and retiree health benefit plan allocation for the U.S. and Puerto Rico currently comprises approximately 80 percent growth investments and 20 percent fixed-income investments. The growth investment allocation encompasses U.S. and international public equity securities, hedge funds, private equity-like investments, and real estate. These portfolio allocations are intended to reduce overall risk by providing diversification, while seeking moderate to high returns over the long term.

Public equity securities are well diversified and invested in U.S. and international small-to-large companies across various asset managers and styles. The remaining portion of the growth portfolio is invested in private alternative investments.

Fixed-income investments primarily consist of fixed-income securities in U.S. treasuries and agencies, emerging market debt obligations, corporate bonds, mortgage-backed securities, and commercial mortgage-backed obligations.

Hedge funds are privately owned institutional investment funds that generally have moderate liquidity. Hedge funds seek specified levels of absolute return regardless of overall market conditions, and generally have low correlations to public equity and debt markets. Hedge funds often invest substantially in financial market instruments (stocks, bonds, commodities, currencies, derivatives, etc.) using a very broad range of trading activities to manage portfolio risks. Hedge fund strategies focus primarily on security selection and seek to be neutral with respect to market moves. Common groupings of hedge fund strategies include relative value, tactical, and event driven. Relative value strategies include arbitrage, when the same asset can simultaneously be bought and sold at different prices, achieving an immediate profit. Tactical strategies often take long and short positions to reduce or eliminate overall market risks while seeking a particular investment opportunity. Event strategy opportunities can evolve from specific company announcements such as mergers and acquisitions, and typically have little correlation to overall market directional movements. Our hedge fund investments are made through limited partnership interests primarily in fund-of-funds structures to ensure diversification across many strategies and many individual managers. Plan holdings in hedge funds are valued based on net asset values (NAVs) calculated by each fund or general partner, as applicable, and we have the ability to redeem these investments at NAV.

Private equity-like investment funds typically have low liquidity and are made through long-term partnerships or joint ventures that invest in pools of capital invested in primarily non-publicly traded entities. Underlying investments include venture capital (early stage investing), buyout, and special situation investing. Private equity management firms typically acquire and then reorganize private companies to create increased long term value. Private equity-like funds usually have a limited life of approximately 10-15 years, and require a minimum investment commitment from their limited partners. Our private investments are made both directly into funds and through fund-of-funds structures to ensure broad diversification of management styles and assets across the portfolio. Plan holdings in private equity-like investments are valued using the value reported by the partnership, adjusted for known cash flows and significant events through our reporting date. Values provided by the partnerships are primarily based on analysis of and judgments about the underlying investments. Inputs to these valuations include underlying NAVs, discounted cash flow valuations, comparable market valuations, and may also include adjustments for currency, credit, liquidity and other risks as applicable. The vast majority of these private partnerships provide us with annual audited financial statements including their compliance with fair valuation procedures consistent with applicable accounting standards.

Real estate is composed of both public and private holdings. Real estate investments in registered investment companies that trade on an exchange are classified as Level 1 on the fair value hierarchy. Real estate investments in funds measured at fair value on the basis of NAV provided by the fund manager are classified as Level 3. These NAVs are developed with inputs including discounted cash flow, independent appraisal, and market comparable analyses.

Other assets include cash and cash equivalents and mark-to-market value of derivatives.

The cash value of the trust-owned insurance contract is invested in investment-grade publicly traded equity and fixed-income securities.

Other than hedge funds, private equity-like investments, and real estate, which are discussed above, we determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses.

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2012 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Defined Benefit Pension Plans
Public equity securities
U.S.	$	457.7	$	307.9	$	149.8	$
International	1,905.3		673.3		1,232.0
Fixed income
Developed markets	1,075.4		156.4		915.3		3.7
Emerging markets	402.3				402.3
Private alternative investments
Hedge funds	2,555.5				1,337.4		1,218.1
Equity-like funds	991.2		17.4		63.3		910.5
Real estate	504.3		353.5		8.2		142.6
Other	394.9		140.1		254.8
Total	$	8,286.6	$	1,648.6	$	4,363.1	$	2,274.9
Retiree Health Benefit Plans
Public equity securities
U.S.	$	45.4	$	30.4	$	15.0	$
International	127.7		33.9		93.8
Fixed income
Developed markets	59.4				59.0		0.4
Emerging markets	40.3				40.3
Private alternative investments
Hedge funds	234.0				134.1		99.9
Equity-like funds	81.9						81.9
Cash value of trust owned insurance contract	869.1				869.1
Real estate	35.4		35.4
Other	24.8		6.2		18.6
Total	$	1,518.0	$	105.9	$	1,229.9	$	182.2

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2012.

The activity in the Level 3 investments during the year ended December 31, 2012 was as follows:



	Fixed Income: Developed Markets		Hedge Funds			Equity-like Funds		Real Estate		Total
Defined Benefit Pension Plans
Beginning balance at January 1, 2012	$	—	$	1,248.4		$	870.2	$	138.0	$	2,256.6
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	0.3		18.3			10.1		3.3		32.0
Relating to assets sold during the period	—		(0.2		)	—		—		(0.2		)
Purchases, sales, and settlements, net	2.3		(48.4		)	30.2		1.3		(14.6		)
Transfers into (out of) Level 3	1.1		—			—		—		1.1
Ending balance at December 31, 2012	$	3.7	$	1,218.1		$	910.5	$	142.6	$	2,274.9
Retiree Health Benefit Plans
Beginning balance at January 1, 2012	$	—	$	105.3		$	79.9			$	185.2
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	—		(0.9		)	—				(0.9		)
Relating to assets sold during the period	—		—			—				—
Purchases, sales, and settlements, net	0.3		(4.5		)	2.0				(2.2		)
Transfers into (out of) Level 3	0.1		—			—				0.1
Ending balance at December 31, 2012	$	0.4	$	99.9		$	81.9			$	182.2

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2011 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Defined Benefit Pension Plans
Public equity securities
U.S.	$	454.5	$	317.2	$	137.3	$
International	1,462.4		505.9		956.5
Fixed income
Developed markets	929.1		100.9		828.2
Emerging markets	341.5		0.1		341.4
Private alternative investments
Hedge funds	2,312.6				1,064.2		1,248.4
Equity-like funds	870.2						870.2
Real estate	409.2		271.2				138.0
Other	406.8		177.7		229.1
Total	$	7,186.3	$	1,373.0	$	3,556.7	$	2,256.6
Retiree Health Benefit Plans
Public equity securities
U.S.	$	40.9	$	28.0	$	12.9	$
International	97.1		27.5		69.6
Fixed income
Developed markets	55.3				55.3
Emerging markets	34.6				34.6
Private alternative investments
Hedge funds	213.1				107.8		105.3
Equity-like funds	79.9						79.9
Cash value of trust owned insurance contract	767.9				767.9
Real estate	27.5		27.5
Other	22.7		8.6		14.1
Total	$	1,339.0	$	91.6	$	1,062.2	$	185.2

No material transfers between Level 1, Level 2, or Level 3 occurred during the year ended December 31, 2011.

The activity in the Level 3 investments during the year ended December 31, 2011 was as follows:



	Hedge Funds			Equity-like Funds		Real Estate		Total
Defined Benefit Pension Plans
Beginning balance at January 1, 2011	$	1,241.9		$	802.9	$	126.5	$	2,171.3
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	(8.1		)	34.4		3.9		30.2
Relating to assets sold during the period	(18.1		)	—		—		(18.1		)
Purchases, sales, and settlements, net	32.7			32.9		7.6		73.2
Ending balance at December 31, 2011	$	1,248.4		$	870.2	$	138.0	$	2,256.6

Retiree Health Benefit Plans
Beginning balance at January 1, 2011	$	106.6		$	74.5			$	181.1
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	0.5			3.3				3.8
Relating to assets sold during the period	(1.8		)	—				(1.8		)
Purchases, sales, and settlements, net	—			2.1				2.1
Ending balance at December 31, 2011	$	105.3		$	79.9			$	185.2

For the year ended December 31, 2013, we expect to contribute approximately $60 million to our defined benefit pension plans to satisfy minimum funding requirements for the year. In addition, we expect to contribute approximately $300 million of additional discretionary funding in the aggregate during the year ended December 31, 2013 to several of our global defined benefit pension and post-retirement health benefit plans.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Contingencies	12 Months Ended
Contingencies	Dec. 31, 2012
Loss Contingency, Information about Litigation Matters [Abstract]
Contingencies [Text Block]	Note 15: Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters, and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as specifically noted below with respect to the Alimta Hatch-Waxman Act patent challenges, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Patent Litigation We are engaged in the following U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Hatch-Waxman Act (the Drug Price Competition and Patent Term Restoration Act of 1984). Teva Parenteral Medicines, Inc. (Teva); APP Pharmaceuticals, LLC (APP); and Barr Laboratories, Inc. (Barr) each submitted ANDAs seeking approval to market generic versions of Alimta prior to the expiration of the relevant U.S. patents and data-based pediatric exclusivity period (compound patent licensed from the Trustees of Princeton University and expiring in 2017, vitamin dosage regimen patent expiring in 2022) and alleging the patents are invalid. We, along with Princeton, filed lawsuits in the U.S. District Court for the District of Delaware against Teva, APP, and Barr seeking rulings that the compound patent is valid and infringed. In July 2011, the district court entered judgment in our favor, upholding that patent’s validity. In August 2012, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed the district court's judgment in our favor. Teva and APP filed a petition for en banc review of the CAFC's panel decision, which was denied in November 2012. It is possible that Teva and APP may seek review by the U.S. Supreme Court. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP, Pliva Hrvatska D.O.O., and Barr seeking rulings that our vitamin dosage regimen patent is valid and infringed. Trial in this case is scheduled to begin in August 2013. In January 2012 and April 2012, we filed similar lawsuits against Accord Healthcare Inc. and Apotex Inc., respectively. In addition, generic manufacturers have opposed the European Patent Office's decision to grant a vitamin dosage regimen patent, and are seeking revocation of that patent. We believe the challenges to the Alimta patents are without merit and expect to prevail in this litigation. However, it is not possible to determine the outcome of this litigation, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market. Byetta Product Liability Litigation We have been named as a defendant in approximately 140 Byetta product liability lawsuits involving approximately 520 plaintiffs. Approximately 100 of these lawsuits, covering about 485 plaintiffs, are filed in California and coordinated in a Los Angeles Superior Court. We are aware of approximately 465 additional claimants who have not yet filed suit. The majority of the claims allege damages for pancreatitis. A smaller number of claimants allege that Byetta caused or contributed to their pancreatic cancer. We believe these claims are without merit and are prepared to defend against them vigorously. Diethylstilbestrol Product Liability Litigation In approximately 90 U.S. lawsuits against us involving approximately 90 claimants, plaintiffs seek to recover damages on behalf of children or grandchildren of women who were prescribed diethylstilbestrol (DES) during pregnancy in the 1950s and 1960s. Approximately 80 of these claimants allege that they were indirectly exposed in utero to the medicine and later developed breast cancer as a consequence. We believe these claims are without merit and are prepared to defend against them vigorously. Zyprexa Product Liability Litigation We are a defendant in approximately 10 Zyprexa product liability lawsuits in the U.S. covering approximately 10 plaintiffs. The lawsuits allege a variety of injuries from the use of Zyprexa. The claims seek substantial compensatory and punitive damages and typically accuse us of inadequately testing for and warning about side effects of Zyprexa. Many of the claims also allege that we improperly promoted the drug. We believe these claims are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. In the past several years, we have been unable to obtain product liability insurance due to a very restrictive insurance market. Therefore, for substantially all of our currently marketed products, we have been and expect that we will continue to be completely self-insured for product liability losses. The DES claims are covered by insurance, subject to deductibles and coverage limits. There is no assurance that we will be able to fully collect from our insurance carriers in the future.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2012

Other Comprehensive Income (Loss), Tax [Abstract]

Comprehensive Income (Loss) [Text Block]

Note 16: Other Comprehensive Income (Loss)

The accumulated balances related to each component of other comprehensive income (loss) were as follows:



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2010	$	835.8		$	75.4		$	(3,264.3	)	$	(118.8	)	$	(2,471.9	)
Unrealized gain (loss)				81.1						(9.3		)
Net amount reclassed to net income				(27.6		)				(5.8		)
Other comprehensive income (loss)	(325.1		)	53.5			88.5			(15.1		)	(198.2		)
Balance at December 31, 2010	510.7			128.9			(3,175.8		)	(133.9		)	(2,670.1		)
Unrealized gain (loss)				(59.4		)				32.6
Net amount reclassed to net income				(54.7		)				(5.8		)
Other comprehensive income (loss)	(244.8		)	(114.1		)	(856.4		)	26.8			(1,188.5		)
Balance at December 31, 2011	265.9			14.8			(4,032.2		)	(107.1		)	(3,858.6		)
Unrealized gain (loss)				104.1
Net amount reclassed to net income				(46.4		)				5.9
Other comprehensive income (loss)	160.9			57.7			(163.0		)	5.9			61.5
Balance at December 31, 2012	$	426.8		$	72.5		$	(4,195.2	)	$	(101.2	)	$	(3,797.1	)

The tax effect on the unrealized net gains (losses) on securities was an expense of $30.8 million in 2012, a benefit of $64.4 million in 2011, and an expense of $27.3 million in 2010. The tax effect related to our defined benefit pension and retiree health benefit plans (Note 14) was an expense of $34.4 million in 2012, a benefit of $383.8 million in 2011, and an expense of $60.4 million in 2010. The tax effect on the effective portion of cash flow hedges was not significant for the years ended December 31, 2012, 2011, and 2010. Income taxes were not provided for foreign currency translation.

Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in income.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e716-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e640-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Other-Net, Expense (Income)

12 Months Ended

Dec. 31, 2012

Nonoperating Income (Expense) [Abstract]

Other - Net, Expense (Income) [Text Block]

Note 17: Other—Net, (Income) Expense:

Other—net, (income) expense consisted of the following:



	2012			2011			2010
Income related to prepayment of Amylin's obligation (Note 4)	$	(787.8	)	$	—		$	—
Interest expense	177.8			186.0			185.5
Interest income	(105.0		)	(79.9		)	(51.9		)
Other (income) expense	41.0			72.9			(128.6		)
Other—net, (income) expense	$	(674.0	)	$	179.0		$	5.0

The most significant component of other—net, (income) expense for the year ended December 31, 2012 was the income recognized from the early payment of the exenatide revenue-sharing obligation by Amylin. See Note 4 for additional information. For the year ended December 31, 2011, other—net, (income) expense primarily consists of the impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 7) partially offset by gains on the disposal of investment securities. For the year ended December 31, 2010, other—net, (income) expense primarily consists of damages recovered from generic pharmaceutical companies related to Zyprexa patent litigation in Germany and gains on the disposal of investment securities.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash equivalents

We consider all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. The cost of these investments approximates fair value.

Inventory, Policy [Policy Text Block]

Inventories

Investment, Policy [Policy Text Block]

Investments

Derivatives, Policy [Policy Text Block]

Risk-management instruments

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and other intangibles

Goodwill results from excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not amortized.

Intangible assets with finite lives are capitalized and are amortized over their estimated useful lives, ranging from 3 to 20 years.

Property, Plant and Equipment, Policy [Policy Text Block]

Property and equipment

Commitments and Contingencies, Policy [Policy Text Block]

Litigation and environmental liabilities

Revenue Recognition, Policy [Policy Text Block]

Revenue recognition

Research and Development Expense, Policy [Policy Text Block]

Research and development expenses and acquired research and development

Research and development expenses include the following:


•	Research and development costs, which are expensed as incurred.


•	Milestone payments incurred prior to regulatory approval of the product, which are accrued when the event requiring payment of the milestone occurs.

Acquired IPR&D expense includes the initial costs of IPR&D projects acquired directly in asset acquisitions, unless they have an alternative future use.

Income Tax, Policy [Policy Text Block]

Income taxes

Earnings Per Share, Policy [Policy Text Block]

Earnings per share

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Stock-based compensation

Financial Instruments (Policies)	12 Months Ended
Financial Instruments (Policies)	Dec. 31, 2012
Fair Value Disclosures [Abstract]
Description of Derivative Risk Management Policy	Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings.

- Definition

Description of the entity's objectives and strategies pertaining to the use of derivative instruments and nonderivative hedging instruments in the context of the entity's overall risk management profile, and the risks associated with the use of derivatives. Indicates the purpose of derivative instruments not used for hedging purposes. Qualitative disclosures that describe the entity's objectives and strategies for holding derivatives in the context of an entity's overall risk management profile.

+ References + Details

Segment Information Segment Information (Tables)

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]



ELI LILLY AND COMPANY AND SUBSIDIARIES (Dollars in millions)	Year Ended December 31	2012			2011			2010
Segment revenue—to unaffiliated customers
Human pharmaceutical products
Neuroscience		$	7,575.1		$	9,723.8		$	9,419.0
Endocrinology		6,810.9			6,806.7			6,135.4
Oncology		3,281.6			3,322.2			3,744.5
Cardiovascular		2,632.5			2,486.4			2,171.3
Other pharmaceuticals		266.8			268.8			214.4
Total human pharmaceutical products		20,566.9			22,607.9			21,684.6
Animal health		2,036.5			1,678.6			1,391.4
Total segment revenue		$	22,603.4		$	24,286.5		$	23,076.0

Segment profits
Human pharmaceutical products		$	4,393.4		$	5,837.9		$	6,516.3
Animal health		508.1			301.0			250.9
Total segment profits		$	4,901.5		$	6,138.9		$	6,767.2

Reconciliation of total segment profits to consolidated income before taxes
Segment profits		$	4,901.5		$	6,138.9		$	6,767.2
Other profits (losses)
Income related to prepayment of Amylin's obligation (Note 4)		787.8			—			—
Acquired in-process research and development (Notes 3 and 4)		—			(388.0		)	(50.0		)
Asset impairments, restructuring, and other special charges (Note 5)		(281.1		)	(401.4		)	(192.0		)
Total consolidated income before taxes		$	5,408.2		$	5,349.5		$	6,525.2

Revenue from External Customers by Products and Services [Table Text Block]

Following is the composition of revenue:



	2012		2011		2010
Net product sales	$	21,970.4	$	23,604.8	$	22,442.2
Collaboration and other revenue (Note 4)	633.0		681.7		633.8
Total revenue	$	22,603.4	$	24,286.5	$	23,076.0

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]



(Dollars in millions)	Year Ended December 31	2012		2011		2010
Geographic Information
Revenue—to unaffiliated customers⁽¹⁾
United States		$	12,313.1	$	12,977.2	$	12,865.6
Europe		4,259.7		5,290.9		5,106.4
Japan		2,246.2		2,104.1		1,616.6
Other foreign countries		3,784.4		3,914.3		3,487.4
Revenue		$	22,603.4	$	24,286.5	$	23,076.0

Long-lived assets⁽²⁾
United States		$	5,064.7	$	5,485.3	$	5,333.9
Europe		2,281.1		2,220.2		2,250.7
Japan		101.5		102.9		101.2
Other foreign countries		1,543.2		1,564.0		1,588.4
Long-lived assets		$	8,990.5	$	9,372.4	$	9,274.2


¹	Revenue is attributed to the countries based on the location of the customer.


²	Long-lived assets consist of property and equipment and certain sundry assets.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2012

Accounting Policies [Abstract]

Inventory Disclosure [Text Block]

Inventories at December 31 consisted of the following:



	2012			2011
Finished products	$	834.4		$	786.4
Work in process	1,735.8			1,518.2
Raw materials and supplies	256.1			205.8
	2,826.3			2,510.4
Reduction to LIFO cost	(182.5		)	(210.6		)
Inventories	$	2,643.8		$	2,299.8

Property, Plant and Equipment Disclosure [Text Block]

At December 31, property and equipment consisted of the following:



	2012			2011
Land	$	201.4		$	202.5
Buildings	6,373.8			6,135.7
Equipment	7,542.9			7,219.9
Construction in progress	799.9			1,036.0
	14,918.0			14,594.1
Less accumulated depreciation	(7,157.8		)	(6,833.8		)
Property and equipment, net	$	7,760.2		$	7,760.3

Revenue from External Customers by Products and Services [Table Text Block]

Following is the composition of revenue:



	2012		2011		2010
Net product sales	$	21,970.4	$	23,604.8	$	22,442.2
Collaboration and other revenue (Note 4)	633.0		681.7		633.8
Total revenue	$	22,603.4	$	24,286.5	$	23,076.0

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Collaborations (Tables)

12 Months Ended

Dec. 31, 2012

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue recognized with respect to Erbitux:



	2012		2011		2010
Net product sales	$	76.4	$	87.6	$	71.9
Collaboration and other revenue	320.6		321.6		314.2
Total revenue	$	397.0	$	409.2	$	386.1

Exenatide [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue and other income recognized with respect to exenatide:



	2012		2011		2010
Net product sales	$	207.8	$	179.6	$	168.1
Collaboration and other revenue	70.1		243.1		262.5
Total revenue	$	277.9	$	422.7	$	430.6

Income related to prepayment of Amylin's obligation⁽¹⁾	$	787.8	$	—	$	—

¹ Presented in other-net, (income) expense

Asset Impairments, Restructuring, and Other Special Charges (Tables)

12 Months Ended

Dec. 31, 2012

Other Cost and Expense Disclosure, Operating [Abstract]

Schedule of Other Operating Cost and Expense, by Component [Table Text Block]

The components of the charges included in asset impairments, restructuring, and other special charges in our consolidated statements of operations are described below.



	2012		2011		2010
Severance	$	74.5	$	251.8	$	142.0
Asset impairments and other special charges	206.6		149.6		50.0
Asset impairments, restructuring, and other special charges	$	281.1	$	401.4	$	192.0

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2012

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of December 31, 2012:



	Maturities by Period
	Total		Less Than 1 Year		1-5 Years		6-10 Years		More Than 10 Years
Fair value of debt securities	$	7,569.9	$	1,665.5	$	4,776.5	$	373.9	$	754.0

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following effects of risk-management instruments were recognized in other—net, (income) expense:



	2012			2011			2010
Fair value hedges
Effect from hedged fixed-rate debt	$	51.5		$	259.6		$	149.6
Effect from interest rate contracts	(51.5		)	(259.6		)	(149.6		)
Cash flow hedges
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	9.0			9.0			9.0
Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments	(35.8		)	97.4			12.0

Fair Value, Assets Measured on Recurring Basis [Table Text Block]



					Fair Value Measurements Using
Description	Carrying Amount		Amortized Cost		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)	Fair Value
December 31, 2012
Cash and cash equivalents	$	4,018.8	$	4,018.8	$	3,964.4	$	54.4	$	$	4,018.8
Short-term investments
U.S. government and agencies	$	150.2	$	150.2	$	150.2	$		$	$	150.2
Corporate debt securities	1,503.5		1,501.5				1,503.5			1,503.5
Other securities	11.8		11.8				11.8			11.8
Short-term investments	$	1,665.5	$	1,663.5
Noncurrent investments
U.S. government and agencies	$	1,362.7	$	1,360.3	$	1,122.4	$	240.3	$	$	1,362.7
Corporate debt securities	3,351.3		3,322.9				3,351.3			3,351.3
Mortgage-backed	668.1		677.7				668.1			668.1
Asset-backed	519.0		523.5				519.0			519.0
Other securities	3.3		3.3				3.3			3.3
Marketable equity	175.8		83.0		175.8					175.8
Equity method and other investments⁽¹⁾	233.1		233.1
Noncurrent investments	$	6,313.3	$	6,203.8

December 31, 2011
Cash and cash equivalents	$	5,922.5	$	5,922.5	$	5,264.6	$	657.9	$	$	5,922.5
Short-term investments
U.S. government and agencies	$	362.3	$	362.3	$	351.3	$	11.0	$	$	362.3
Corporate debt securities	600.7		601.1				600.7			600.7
Other securities	11.6		11.6				11.6			11.6
Short-term investments	$	974.6	$	975.0
Noncurrent investments
U.S. government and agencies	$	908.8	$	901.3	$	673.5	$	235.3	$	$	908.8
Corporate debt securities	2,081.3		2,093.3				2,081.3			2,081.3
Mortgage-backed	443.8		479.1				443.8			443.8
Asset-backed	245.0		253.2				245.0			245.0
Other securities	10.0		11.9				8.7		1.3	10.0
Marketable equity	180.8		107.5		180.8					180.8
Equity method and other investments⁽¹⁾	160.1		160.1
Noncurrent investments	$	4,029.8	$	4,006.4


¹	Fair value not applicable

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
Long-term debt, including current portion
December 31, 2012	$	(5,531.3	)	$	$	(5,996.6	)	$	$	(5,996.6	)
December 31, 2011	(6,981.5		)		(7,451.5		)		(7,451.5		)

Fair Value, by Balance Sheet Grouping [Table Text Block]



				Fair Value Measurements Using
Description	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Fair Value
December 31, 2012
Risk-management instruments
Interest rate contracts designated as hedging instruments
Sundry	$	589.4		$	$	589.4		$	$	589.4
Foreign exchange contracts not designated as hedging instruments
Other receivables	11.0				11.0				11.0
Other current liabilities	(17.5		)		(17.5		)		(17.5		)

December 31, 2011
Risk-management instruments
Interest rate contracts designated as hedging instruments
Other receivables	$	6.1		$	$	6.1		$	$	6.1
Sundry	531.7				531.7				531.7
Foreign exchange contracts not designated as hedging instruments
Other receivables	16.2				16.2				16.2
Other current liabilities	(25.9		)		(25.9		)		(25.9		)

Available-for-sale Securities [Table Text Block]



	2012		2011
Unrealized gross gains	$	140.5	$	103.0
Unrealized gross losses	29.0		80.0
Fair value of securities in an unrealized gain position	5,246.0		2,498.9
Fair value of securities in an unrealized loss position	2,102.0		2,164.4

Gain (Loss) on Investments [Table Text Block]

Activity related to our available-for-sale investment portfolio was as follows:



	2012		2011		2010
Proceeds from sales	$	6,529.8	$	2,268.3	$	760.3
Realized gross gains on sales	82.3		140.0		110.7
Realized gross losses on sales	10.9		9.9		4.8

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13467-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring and/or nonrecurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References + Details

- Definition

Tabular disclosure of the realized and unrealized gains and losses reported in the statement of income which have resulted from the sale and holding of marketable securities, respectively, as well as the sale or disposal of cost method investments. Such amounts would include realized gains and losses on the sale or disposal of trading, available-for-sale, and held-to-maturity securities, unrealized gains and losses on trading securities, unrealized gains and losses on available-for-sale and held-to-maturity securities transferred to the trading securities category, realized gains and losses on the sale or disposal of cost method investments, and losses recognized for other than temporary impairments (OTTI) of such investments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (c)-(e)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.M)
-URI http://asc.fasb.org/extlink&oid=6784337&loc=d3e87990-122713

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 7, 13, 16, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 21
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section M

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Goodwill and Other Intangibles (Tables)

12 Months Ended

Dec. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Assets [Table Text Block]

Goodwill and other indefinite-lived intangible assets at December 31 were as follows:



	2012		2011
Indefinite-lived intangible assets
Goodwill	$	1,501.3	$	1,434.7
In-process research and development	65.0		474.9
Total indefinite-lived intangible assets	$	1,566.3	$	1,909.6

Schedule of Intangible Assets and Goodwill [Table Text Block]

The components of finite-lived intangible assets at December 31 were as follows:



	2012							2011
Description	Carrying Amount— Gross		Accumulated Amortization			Carrying Amount— Net		Carrying Amount— Gross		Accumulated Amortization			Carrying Amount— Net
Finite-lived intangible assets
Marketed products	$	5,107.9	$	(1,987.0	)	$	3,120.9	$	4,624.9	$	(1,481.2	)	$	3,143.7
Other	129.5		(64.0		)	65.5		117.3		(42.5		)	74.8
Total finite-lived intangible assets	$	5,237.4	$	(2,051.0	)	$	3,186.4	$	4,742.2	$	(1,523.7	)	$	3,218.5

Borrowings (Tables)

12 Months Ended

Dec. 31, 2012

Long-term Debt, Current and Noncurrent [Abstract]

Schedule of Debt [Table Text Block]

Long-term debt at December 31 consisted of the following:



	2012			2011
3.55 to 7.13 percent notes (due 2012-2037)	$	4,887.3		$	6,387.4
Other, including capitalized leases	37.4			37.6
Fair value adjustment	606.6			556.5
	5,531.3			6,981.5
Less current portion	(11.9		)	(1,516.8		)
Long-term debt	$	5,519.4		$	5,464.7

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2012

Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]

Schedule of Nonvested Performance-based Units Activity [Table Text Block]



(Percents)	2012	2011	2010
Expected dividend yield	4.50	4.90	4.50
Risk-free interest rate	.10-.36	.20-1.36	.10-1.36
Range of volatilities	22.40-25.64	27.61-29.10	28.00-28.69

A summary of the SVA activity is presented below:



	Units Attributable to SVAs (in thousands)
Outstanding at January 1, 2010	2,760
Granted	1,987
Issued	(365	)
Forfeited or expired	(745	)
December 31, 2010	3,637
Granted	1,830
Issued	(428	)
Forfeited or expired	(740	)
December 31, 2011	4,299
Granted	1,742
Issued	(973	)
Forfeited or expired	(165	)
December 31, 2012	4,903

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Stock option activity during the year ended December 31, 2012 is summarized below:



	Shares of Common Stock Attributable to Options (in thousands)		Weighted-Average Exercise Price of Options		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2012	36,556		$	66.22
Exercised	(50	)	20.37
Forfeited or expired	(9,274	)	73.28
Outstanding at December 31, 2012	27,232		63.89		1.2	$	0.4
Exercisable at December 31, 2012	27,232		63.89		1.2	0.4

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2012

Stockholders' Equity Note [Abstract]

Schedule of Stockholders Equity [Table Text Block]

Changes in certain components of shareholders' equity were as follows:



	Additional Paid-in Capital			Retained Earnings			Deferred Costs - ESOP			Common Stock in Treasury
										Shares (in thousands)		Amount
Balance at January 1, 2010	$	4,635.6		$	9,830.4		$	(77.4	)	882		$	98.5
Net income				5,069.5
Cash dividends declared per share: $1.96				(2,167.3		)
Retirement of treasury shares	(1.0		)							(28	)	(1.0		)
Issuance of stock under employee stock plans-net	(87.6		)							10		(1.1		)
Stock-based compensation	231.0
ESOP transactions	20.5						25.0
Balance at December 31, 2010	4,798.5			12,732.6			(52.4		)	864		96.4
Net income				4,347.7
Cash dividends declared per share: $1.96				(2,182.5		)
Retirement of treasury shares	(0.1		)							(1	)	(0.1		)
Issuance of stock under employee stock plans-net	(108.7		)							(10	)	(1.0		)
Stock-based compensation	147.4
ESOP transactions	49.7						52.4
Balance at December 31, 2011	4,886.8			14,897.8			—			853		95.3
Net income				4,088.6
Cash dividends declared per share: $1.96				(2,186.5		)
Retirement of treasury shares				(711.7		)				(14,912	)	(721.1		)
Purchase for treasury										16,918		819.2
Issuance of stock under employee stock plans-net	(65.2		)							(9	)	(1.0		)
Stock-based compensation	141.5
Balance at December 31, 2012	$	4,963.1		$	16,088.2		$	—		2,850		$	192.4

Earnings (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2012

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

Following is a reconciliation of the denominators used in computing earnings per share:



	2012		2011		2010
	(Shares in thousands)
Income available to common shareholders	$	4,088.6	$	4,347.7	$	5,069.5
Basic earnings per share
Weighted-average number of common shares outstanding, including incremental shares	1,113,178		1,113,923		1,105,788
Basic earnings per share	$	3.67	$	3.90	$	4.58
Diluted earnings per share
Weighted-average number of common shares outstanding, including incremental shares and stock options	1,117,294		1,113,967		1,105,813
Diluted earnings per share	$	3.66	$	3.90	$	4.58

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

Following is the composition of income tax expense:



	2012		2011			2010
Current
Federal	$	596.8	$	671.4		$	376.2
Foreign	540.6		759.5			513.9
State	56.2		(22.9		)	23.3
Total current tax expense	1,193.6		1,408.0			913.4
Deferred
Federal	87.0		(398.5		)	624.4
Foreign	29.9		(34.7		)	(55.2		)
State	9.1		27.0			(26.9		)
Total deferred tax expense (benefit)	126.0		(406.2		)	542.3
Income taxes	$	1,319.6	$	1,001.8		$	1,455.7

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Significant components of our deferred tax assets and liabilities as of December 31 are as follows:



	2012			2011
Deferred tax assets
Compensation and benefits	$	1,081.8		$	1,286.5
Tax credit carryforwards and carrybacks	703.2			695.3
Tax loss carryforwards and carrybacks	370.1			406.1
Asset purchases	366.8			386.2
Sale of intangibles	278.6			207.1
Debt	232.8			214.9
Intercompany profit in inventories	159.6			277.2
Product return reserves	153.8			146.2
Contingencies	113.2			94.5
Other	361.5			292.8
Total gross deferred tax assets	3,821.4			4,006.8
Valuation allowances	(675.8		)	(611.9		)
Total deferred tax assets	3,145.6			3,394.9
Deferred tax liabilities
Unremitted earnings	(920.4		)	(940.2		)
Intangibles	(708.8		)	(797.6		)
Inventories	(573.4		)	(489.2		)
Property and equipment	(407.1		)	(451.0		)
Financial instruments	(257.0		)	(196.9		)
Total deferred tax liabilities	(2,866.7		)	(2,874.9		)
Deferred tax assets - net	$	278.9		$	520.0

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

Following is a reconciliation of the income tax expense applying the U.S. federal statutory rate to income before income taxes to reported income tax expense:



	2012			2011			2010
Income tax at the U.S. federal statutory tax rate	$	1,892.9		$	1,872.3		$	2,283.8
Add (deduct)
International operations, including Puerto Rico	(593.8		)	(796.7		)	(823.3		)
U.S. health care reform	59.8			62.9			85.1
General business credits	(11.2		)	(80.8		)	(83.2		)
IRS audit conclusion	—			(85.3		)	—
Other	(28.1		)	29.4			(6.7		)
Income taxes	$	1,319.6		$	1,001.8		$	1,455.7

Summary of Income Tax Contingencies [Table Text Block]

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:



	2012			2011			2010
Beginning balance at January 1	$	1,274.8		$	1,619.6		$	1,351.2
Additions based on tax positions related to the current year	141.5			89.4			186.2
Additions for tax positions of prior years	70.1			390.0			117.0
Reductions for tax positions of prior years	(38.5		)	(492.3		)	(30.2		)
Settlements	(9.2		)	(326.3		)	(0.1		)
Lapses of statutes of limitation	(4.6		)	(2.6		)	(7.0		)
Changes related to the impact of foreign currency translation	(0.3		)	(3.0		)	2.5
Balance at December 31	$	1,433.8		$	1,274.8		$	1,619.6

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References + Details

Retirement Benefits (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Changes in Accumulated Postemployment Benefit Obligations [Table Text Block]



	Defined Benefit Pension Plans						Retiree Health Benefit Plans
	2012			2011			2012			2011
Change in benefit obligation
Benefit obligation at beginning of year	$	9,191.2		$	8,115.0		$	2,308.6		$	2,088.5
Service cost	253.1			236.3			63.3			72.4
Interest cost	455.1			447.9			114.9			118.0
Actuarial (gain) loss	834.0			794.7			(57.0		)	110.2
Benefits paid	(404.2		)	(400.1		)	(67.2		)	(77.9		)
Plan amendments	(0.6		)	10.0			(28.4		)	1.1
Foreign currency exchange rate changes and other adjustments	95.2			(12.6		)	3.5			(3.7		)
Benefit obligation at end of year	10,423.8			9,191.2			2,337.7			2,308.6

Schedule of Changes in Fair Value of Plan Assets [Table Text Block]



Change in plan assets
Fair value of plan assets at beginning of year	7,186.3		6,983.0		1,339.0		1,327.7
Actual return on plan assets	922.7		209.2		183.4		16.6
Employer contribution	469.7		402.4		62.8		72.6
Benefits paid	(404.2	)	(400.1	)	(67.2	)	(77.9	)
Foreign currency exchange rate changes and other adjustments	112.1		(8.2	)	—		—
Fair value of plan assets at end of year	8,286.6		7,186.3		1,518.0		1,339.0

Schedule of Net Funded Status [Table Text Block]



Funded status	(2,137.2		)	(2,004.9		)	(819.7		)	(969.6		)
Unrecognized net actuarial loss	5,187.5			4,857.5			1,156.7			1,367.4
Unrecognized prior service (benefit) cost	54.9			57.3			(203.4		)	(215.1		)
Net amount recognized	$	3,105.2		$	2,909.9		$	133.6		$	182.7

Schedule of Amounts Recognized in Balance Sheet [Table Text Block]



Amounts recognized in the consolidated balance sheet consisted of:
Prepaid expenses and other	$	125.5		$	160.8		$	—		$	—
Other current liabilities	(61.2		)	(57.5		)	(8.9		)	(9.3		)
Accrued retirement benefit	(2,201.6		)	(2,108.2		)	(810.8		)	(960.3		)
Accumulated other comprehensive loss before income taxes	5,242.5			4,914.8			953.3			1,152.3
Net amount recognized	$	3,105.2		$	2,909.9		$	133.6		$	182.7

Schedule of Assumptions Used [Table Text Block]

The following represents our weighted-average assumptions as of December 31:



	Defined Benefit Pension Plans			Retiree Health Benefit Plans
(Percents)	2012	2011	2010	2012	2011	2010
Weighted-average assumptions as of December 31
Discount rate for benefit obligation	4.3	5.0	5.6	4.3	5.1	5.8
Discount rate for net benefit costs	5.0	5.6	5.9	5.1	5.8	6.0
Rate of compensation increase for benefit obligation	3.4	3.7	3.7
Rate of compensation increase for net benefit costs	3.7	3.7	3.7
Expected return on plan assets for net benefit costs	8.4	8.5	8.8	8.8	8.8	9.0

Schedule of Expected Benefit Payments [Table Text Block]

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows:



	2013			2014			2015			2016			2017			2018-2022
Defined benefit pension plans	$	427.1		$	434.0		$	445.3		$	459.1		$	473.8		$	2,646.0

Retiree health benefit plans-gross	$	111.6		$	114.5		$	119.4		$	124.6		$	129.9		$	729.7
Medicare rebates	(6.3		)	(9.5		)	(10.2		)	(10.6		)	(10.9		)	(49.5		)
Retiree health benefit plans-net	$	105.3		$	105.0		$	109.2		$	114.0		$	119.0		$	680.2

Schedule of Net Benefit Costs [Table Text Block]

Net pension and retiree health benefit expense included the following components:



	Defined Benefit Pension Plans									Retiree Health Benefit Plans
	2012			2011			2010			2012			2011			2010
Components of net periodic benefit cost
Service cost	$	253.1		$	236.3		$	219.2		$	63.3		$	72.4		$	56.5
Interest cost	455.1			447.9			431.6			114.9			118.0			121.4
Expected return on plan assets	(684.8		)	(685.9		)	(638.2		)	(127.2		)	(129.4		)	(122.6		)
Amortization of prior service (benefit) cost	4.2			8.6			8.8			(39.8		)	(42.9		)	(37.2		)
Recognized actuarial loss	285.7			200.4			163.0			98.4			88.7			85.0
Net periodic benefit cost	$	313.3		$	207.3		$	184.4		$	109.6		$	106.8		$	103.1

Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]

The following represents the amounts recognized in other comprehensive income (loss) for the year ended December 31, 2012:



	Defined Benefit Pension Plans			Retiree Health Benefit Plans
Actuarial (gain) loss arising during period	$	598.9		$	(113.2	)
Plan amendments during period	(0.6		)	(28.4		)
Amortization of prior service (benefit) cost included in net income	(4.2		)	39.8
Amortization of net actuarial loss included in net income	(285.7		)	(98.4		)
Foreign currency exchange rate changes	19.3			1.1
Total other comprehensive (income) loss during period	$	327.7		$	(199.1	)

Schedule of Allocation of Plan Assets [Table Text Block]

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2012 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Defined Benefit Pension Plans
Public equity securities
U.S.	$	457.7	$	307.9	$	149.8	$
International	1,905.3		673.3		1,232.0
Fixed income
Developed markets	1,075.4		156.4		915.3		3.7
Emerging markets	402.3				402.3
Private alternative investments
Hedge funds	2,555.5				1,337.4		1,218.1
Equity-like funds	991.2		17.4		63.3		910.5
Real estate	504.3		353.5		8.2		142.6
Other	394.9		140.1		254.8
Total	$	8,286.6	$	1,648.6	$	4,363.1	$	2,274.9
Retiree Health Benefit Plans
Public equity securities
U.S.	$	45.4	$	30.4	$	15.0	$
International	127.7		33.9		93.8
Fixed income
Developed markets	59.4				59.0		0.4
Emerging markets	40.3				40.3
Private alternative investments
Hedge funds	234.0				134.1		99.9
Equity-like funds	81.9						81.9
Cash value of trust owned insurance contract	869.1				869.1
Real estate	35.4		35.4
Other	24.8		6.2		18.6
Total	$	1,518.0	$	105.9	$	1,229.9	$	182.2

The fair values of our defined benefit pension plan and retiree health plan assets as of December 31, 2011 by asset category are as follows:



			Fair Value Measurements Using
Asset Class	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Defined Benefit Pension Plans
Public equity securities
U.S.	$	454.5	$	317.2	$	137.3	$
International	1,462.4		505.9		956.5
Fixed income
Developed markets	929.1		100.9		828.2
Emerging markets	341.5		0.1		341.4
Private alternative investments
Hedge funds	2,312.6				1,064.2		1,248.4
Equity-like funds	870.2						870.2
Real estate	409.2		271.2				138.0
Other	406.8		177.7		229.1
Total	$	7,186.3	$	1,373.0	$	3,556.7	$	2,256.6
Retiree Health Benefit Plans
Public equity securities
U.S.	$	40.9	$	28.0	$	12.9	$
International	97.1		27.5		69.6
Fixed income
Developed markets	55.3				55.3
Emerging markets	34.6				34.6
Private alternative investments
Hedge funds	213.1				107.8		105.3
Equity-like funds	79.9						79.9
Cash value of trust owned insurance contract	767.9				767.9
Real estate	27.5		27.5
Other	22.7		8.6		14.1
Total	$	1,339.0	$	91.6	$	1,062.2	$	185.2

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The activity in the Level 3 investments during the year ended December 31, 2012 was as follows:



	Fixed Income: Developed Markets		Hedge Funds			Equity-like Funds		Real Estate		Total
Defined Benefit Pension Plans
Beginning balance at January 1, 2012	$	—	$	1,248.4		$	870.2	$	138.0	$	2,256.6
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	0.3		18.3			10.1		3.3		32.0
Relating to assets sold during the period	—		(0.2		)	—		—		(0.2		)
Purchases, sales, and settlements, net	2.3		(48.4		)	30.2		1.3		(14.6		)
Transfers into (out of) Level 3	1.1		—			—		—		1.1
Ending balance at December 31, 2012	$	3.7	$	1,218.1		$	910.5	$	142.6	$	2,274.9
Retiree Health Benefit Plans
Beginning balance at January 1, 2012	$	—	$	105.3		$	79.9			$	185.2
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	—		(0.9		)	—				(0.9		)
Relating to assets sold during the period	—		—			—				—
Purchases, sales, and settlements, net	0.3		(4.5		)	2.0				(2.2		)
Transfers into (out of) Level 3	0.1		—			—				0.1
Ending balance at December 31, 2012	$	0.4	$	99.9		$	81.9			$	182.2

The activity in the Level 3 investments during the year ended December 31, 2011 was as follows:



	Hedge Funds			Equity-like Funds		Real Estate		Total
Defined Benefit Pension Plans
Beginning balance at January 1, 2011	$	1,241.9		$	802.9	$	126.5	$	2,171.3
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	(8.1		)	34.4		3.9		30.2
Relating to assets sold during the period	(18.1		)	—		—		(18.1		)
Purchases, sales, and settlements, net	32.7			32.9		7.6		73.2
Ending balance at December 31, 2011	$	1,248.4		$	870.2	$	138.0	$	2,256.6

Retiree Health Benefit Plans
Beginning balance at January 1, 2011	$	106.6		$	74.5			$	181.1
Actual return on plan assets, including changes in foreign exchange rates:
Relating to assets still held at the reporting date	0.5			3.3				3.8
Relating to assets sold during the period	(1.8		)	—				(1.8		)
Purchases, sales, and settlements, net	—			2.1				2.1
Ending balance at December 31, 2011	$	105.3		$	79.9			$	185.2

Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2012

Other Comprehensive Income (Loss), Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

The accumulated balances related to each component of other comprehensive income (loss) were as follows:



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Beginning balance at January 1, 2010	$	835.8		$	75.4		$	(3,264.3	)	$	(118.8	)	$	(2,471.9	)
Unrealized gain (loss)				81.1						(9.3		)
Net amount reclassed to net income				(27.6		)				(5.8		)
Other comprehensive income (loss)	(325.1		)	53.5			88.5			(15.1		)	(198.2		)
Balance at December 31, 2010	510.7			128.9			(3,175.8		)	(133.9		)	(2,670.1		)
Unrealized gain (loss)				(59.4		)				32.6
Net amount reclassed to net income				(54.7		)				(5.8		)
Other comprehensive income (loss)	(244.8		)	(114.1		)	(856.4		)	26.8			(1,188.5		)
Balance at December 31, 2011	265.9			14.8			(4,032.2		)	(107.1		)	(3,858.6		)
Unrealized gain (loss)				104.1
Net amount reclassed to net income				(46.4		)				5.9
Other comprehensive income (loss)	160.9			57.7			(163.0		)	5.9			61.5
Balance at December 31, 2012	$	426.8		$	72.5		$	(4,195.2	)	$	(101.2	)	$	(3,797.1	)

Other - Net, Expense (Income) (Tables)

12 Months Ended

Dec. 31, 2012

Nonoperating Income (Expense) [Abstract]

Schedule of Other Nonoperating Income (Expense) [Table Text Block]

Other—net, (income) expense consisted of the following:



	2012			2011			2010
Income related to prepayment of Amylin's obligation (Note 4)	$	(787.8	)	$	—		$	—
Interest expense	177.8			186.0			185.5
Interest income	(105.0		)	(79.9		)	(51.9		)
Other (income) expense	41.0			72.9			(128.6		)
Other—net, (income) expense	$	(674.0	)	$	179.0		$	5.0

Segment Information Segment Information (Details) - USD ($) $ in Millions	12 Months Ended			36 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenue	$ 22,603.4	$ 24,286.5	$ 23,076.0
Long-Lived Assets	8,990.5	9,372.4	9,274.2	$ 8,990.5
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	4,901.5	6,138.9	6,767.2
Restructuring, Settlement and Impairment Provisions	(281.1)	(401.4)	(192.0)
Income before income taxes	5,408.2	5,349.5	6,525.2
Acquired in-process research and development	0.0	388.0	50.0
Gain (Loss) on Contract Termination	$ 787.8	0.0	0.0
Accounts Receivable, Minimum [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	9.00%
Accounts Receivable, Maximum [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	14.00%
Customer Concentration Risk, Minimum [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage				10.00%
Customer Concentration Risk, Maximum [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage				16.00%
United States [Member]
Segment Reporting Information [Line Items]
Revenue	$ 12,313.1	12,977.2	12,865.6
Long-Lived Assets	5,064.7	5,485.3	5,333.9	$ 5,064.7
Europe [Member]
Segment Reporting Information [Line Items]
Revenue	4,259.7	5,290.9	5,106.4
Long-Lived Assets	2,281.1	2,220.2	2,250.7	2,281.1
Japan [Member]
Segment Reporting Information [Line Items]
Revenue	2,246.2	2,104.1	1,616.6
Long-Lived Assets	101.5	102.9	101.2	101.5
Other Foreign Countries [Member]
Segment Reporting Information [Line Items]
Revenue	3,784.4	3,914.3	3,487.4
Long-Lived Assets	1,543.2	1,564.0	1,588.4	$ 1,543.2
Neuroscience [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	7,575.1	9,723.8	9,419.0
Endocrinology [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	6,810.9	6,806.7	6,135.4
Oncology [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	3,281.6	3,322.2	3,744.5
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	2,632.5	2,486.4	2,171.3
Other Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	266.8	268.8	214.4
Pharmaceutical Products Total [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	20,566.9	22,607.9	21,684.6
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	4,393.4	5,837.9	6,516.3
Animal Health [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information, Revenue for Reportable Segment	2,036.5	1,678.6	1,391.4
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	$ 508.1	$ 301.0	$ 250.9

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Percentage of LIFO Inventory	40.00%
Average Remaining Maturity of Foreign Currency Derivatives	12 months
Finished products	$ 834.4	$ 786.4
Work in process	1,735.8	1,518.2
Raw materials and supplies	256.1	205.8
Inventory, Gross, Total	2,826.3	2,510.4
Reduction to LIFO cost	(182.5)	(210.6)
Inventories	$ 2,643.8	2,299.8
Finite-Lived Intangible Assets, Useful Life, Minimum	9 years
Land	$ 201.4	202.5
Buildings	6,373.8	6,135.7
Equipment	7,542.9	7,219.9
Construction in progress	799.9	1,036.0
Property and equipment, gross	14,918.0	14,594.1
Less accumulated depreciation	(7,157.8)	(6,833.8)
Property and equipment, net	7,760.2	7,760.3
Depreciation	754.0	732.4	$ 749.1
Interest Costs, Capitalized During Period	21.0	25.7	26.0
Operating Leases, Rent Expense	285.8	267.4	255.7
Sales Revenue, Goods, Net	21,970.4	23,604.8	22,442.2
Collaboration and other revenue	633.0	681.7	633.8
Revenue	$ 22,603.4	$ 24,286.5	$ 23,076.0
Minimum [Member]
Finite-Lived Intangible Assets, Useful Life, Minimum	3 years
Minimum [Member] \| Building [Member]
Property, Plant and Equipment, Useful Life, Minimum	12 years
Minimum [Member] \| Equipment [Member]
Property, Plant and Equipment, Useful Life, Minimum	3 years
Maximum [Member]
Finite-Lived Intangible Assets, Useful Life, Minimum	20 years
Maximum [Member] \| Building [Member]
Property, Plant and Equipment, Useful Life, Minimum	50 years
Maximum [Member] \| Equipment [Member]
Property, Plant and Equipment, Useful Life, Minimum	18 years

Implementation of New Financial Accounting Pronouncements (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 170.7	$ 178.0

Acquisitions (Details) $ in Millions	12 Months Ended
Acquisitions (Details) $ in Millions	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Feb. 17, 2012 USD ($)	Jul. 07, 2011 USD ($)	Dec. 20, 2010 USD ($)	Jul. 20, 2010 USD ($)	May 28, 2010 USD ($)
Business Acquisition, Products or Other Assets Acquired					50
Acquired in-process research and development	$ 0.0	$ 388.0	$ 50.0
Business Acquisition [Member]
Acquired Indefinite-lived Intangible Asset, Amount	$ 1.6	29.6	598.0
Janssen Pharmaceutica NV (J&J) [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total					$ 307.8
Business Acquisition, Purchase Price Allocation, Assets Acquired					234.4
Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable					29.6
Business Acquisition, Purchase Price Allocation, Net Tangible Assets					$ 43.8
Avid Radiopharmaceuticals [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total						$ 346.1
Cash paid for acquisition						286.3
Business Acquisition, Contingent Consideration, Potential Cash Payment						550.0
Business Acquisition, Contingent Consideration, at Fair Value						59.8
Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable						334.0
Business Acquisition, Purchase Price Allocation, Goodwill						119.6
Business Acquisition, Purchase Price Allocation, Other Noncurrent Liabilities						116.9
Business Acquisition, Purchase Price Allocation, Net Tangible Assets						$ 9.4
Alnara Pharmaceuticals [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total							$ 291.7
Cash paid for acquisition							188.7
Business Acquisition, Contingent Consideration, Potential Cash Payment							200.0
Business Acquisition, Contingent Consideration, at Fair Value							103.0
Business Acquisition, Purchase Price Allocation, Intangible Assets Not Amortizable							264.0
Business Acquisition, Purchase Price Allocation, Goodwill							100.5
Business Acquisition, Purchase Price Allocation, Other Noncurrent Liabilities							92.4
Business Acquisition, Purchase Price Allocation, Net Tangible Assets							$ 19.6
Animal Health Sligo [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total								$ 148.4
Business Acquisition, Purchase Price Allocation, Assets Acquired								76.2
Business Acquisition, Purchase Price Allocation, Net Tangible Assets								$ 72.2
ChemGen [Member]
Business Acquisition, Cost of Acquired Entity, Purchase Price, Total				$ 206.9
Business Acquisition, Purchase Price Allocation, Assets Acquired				151.5
Business Acquisition, Purchase Price Allocation, Net Tangible Assets				$ 55.4
Asset Acquiisition [Member]
Acquired Indefinite-lived Intangible Asset, Amount		$ 388.0	$ 50.0

Collaborations (Details) € in Millions	1 Months Ended			3 Months Ended				11 Months Ended	12 Months Ended
Collaborations (Details) € in Millions	Aug. 31, 2012 USD ($)	Nov. 30, 2011 USD ($)	Dec. 31, 2009 USD ($)	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($)	Mar. 31, 2010 USD ($)	Nov. 30, 2011	Dec. 31, 2012 EUR (€)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Sales Revenue, Goods, Net										$ 21,970,400,000	$ 23,604,800,000	$ 22,442,200,000
Collaboration and other revenue										633,000,000	681,700,000	633,800,000
Revenue										22,603,400,000	24,286,500,000	23,076,000,000
Other Nonoperating Income (Expense)										(41,000,000)	(72,900,000)	128,600,000
Research and Development Expense										5,278,100,000	5,020,800,000	4,884,200,000
Proceeds from prepayment of revenue-sharing obligation										1,212,100,000	0	0
Collaborative Arrangement, Income Statement Classification and Amounts										261,500,000	219,200,000	174,500,000
Acquired in-process research and development										0	388,000,000	50,000,000
Erbitux [Member]
Sales Revenue, Goods, Net										76,400,000	87,600,000	71,900,000
Collaboration and other revenue										320,600,000	321,600,000	314,200,000
Revenue										397,000,000	409,200,000	386,100,000
Effient [Member]
Sales Revenue, Goods, Net										457,200,000	302,500,000	115,000,000
Amylin [Member]
Other Nonoperating Income (Expense)											0	0
Proceeds from prepayment of revenue-sharing obligation	$ 1,210,000,000
Collaborative Arrangement, Rights and Obligations		$ 250,000,000
Exenatide [Member]
Sales Revenue, Goods, Net										207,800,000	179,600,000	168,100,000
Collaboration and other revenue										70,100,000	243,100,000	262,500,000
Revenue										277,900,000	422,700,000	430,600,000
Other Nonoperating Income (Expense)										787,800,000
Boerhringer Ingelheim (BI) [Member]
Acquired in-process research and development						$ 388,000,000
Sales NEW [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		15.00%
Revenue Share [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations	$ 1,260,000,000
Revenue Share [Member] \| Exenatide Once Weekly [Member]
Deferred Revenue, Current										$ 490,000,000
Secured Note [Member] \| Amylin [Member]
Proceeds from Sales of Business, Affiliate and Productive Assets		$ 1,200,000,000
Debt Instrument, Interest Rate, Stated Percentage										9.50%
Profit and Development and Marketing Share [Member] \| Effient [Member]
Collaborative Arrangement, Rights and Obligations Percent									50.00%	50.00%
Prepaid Selling and Marketing Expense [Member] \| Duloxetine BI [Member]
Collaborative Arrangement, Rights and Obligations							$ 400,000,000
Royalty Payments Received [Member] \| Solanezumab [Member]
Collaborative Arrangement, Rights and Obligations										$ 8
Research and Development Exp [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent			30.00%
Milestone Payments [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations		$ 150,000,000
Milestone Payments [Member] \| TPG-Axon [Member]
Collaborative Arrangement, Rights and Obligations				$ 70,000,000
Milestone Payments [Member] \| BI compounds [Member]
Collaborative Arrangement, Rights and Obligations									€ 300.0		478,700,000
Milestone Payments [Member] \| LLY compounds [Member]
Collaborative Arrangement, Rights and Obligations										300,000,000
Milestone Payments [Member] \| LLY optional compound [Member]
Collaborative Arrangement, Rights and Obligations										525,000,000
Milestone Payments, Development and Regulatory [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations			$ 515,000,000							$ 50,000,000		49,000,000
Milestone Payments, Sales-based [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations			$ 150,000,000
Loan Commitment [Member] \| Exenatide Once Weekly [Member]
Payments to Fund Long-term Loans to Related Parties					$ 165,000,000
Royalty [Member] \| Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent			20.00%
Funding Commitment [Member] \| Necitumumab [Member]
Collaborative Arrangement, Rights and Obligations, Term of Arrangement									18 months	18 months
United States [Member]
Revenue										$ 12,313,100,000	$ 12,977,200,000	$ 12,865,600,000
United States [Member] \| Revenue Share [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		65.00%
United States [Member] \| Gross Margin Share [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent								50.00%
United States [Member] \| Research and Development and Marketing and Selling Expense [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent								50.00%
Outside the United States [Member] \| Sales NEW [Member] \| Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent								100.00%
Outside the United States [Member] \| Revenue Share [Member] \| Amylin [Member]
Collaborative Arrangement, Rights and Obligations Percent		35.00%

Asset Impairments, Restructuring, and Other Special Charges (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Schedule of Other Operating Cost and Expense, by Component [Table Text Block]

The components of the charges included in asset impairments, restructuring, and other special charges in our consolidated statements of operations are described below.



	2012		2011		2010
Severance	$	74.5	$	251.8	$	142.0
Asset impairments and other special charges	206.6		149.6		50.0
Asset impairments, restructuring, and other special charges	$	281.1	$	401.4	$	192.0

Severance Costs

$ 74.5

$ 251.8

$ 142.0

Asset Impairment Charges

206.6

149.6

50.0

Restructuring, Settlement and Impairment Provisions, Total

281.1

401.4

192.0

Xigris [Member]

Asset Impairment Charges

20.0

85.0

Leases [Member]

Asset Impairment Charges

$ 56.1

$ 50.0

Device Delivery Platform [Member]

Asset Impairment Charges

64.0

Liprotamase [Member]

Asset Impairment Charges

$ 122.6

- Definition

The charge against earnings in the period for known and estimated costs of termination benefits provided to current employees that are involuntarily terminated under a benefit arrangement associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination or a discontinued operation as defined by generally accepted accounting principles and costs associated with one-time termination benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(10)
-URI http://asc.fasb.org/extlink&oid=21915506&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5-8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 8-13, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS146-1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 112
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Financial Instruments (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2009 USD ($)	Dec. 31, 2012 EUR (€)	Dec. 31, 2012 USD ($)	Jun. 30, 2012 USD ($)
Proceeds from Sale of Available-for-sale Securities	$ 6,529.8	$ 2,268.3	$ 760.3
Long-term Debt		(6,981.5)				$ (5,531.3)
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets	90.00%
Maximum Remaining Maturity of Foreign Currency Derivatives	45 days
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate					100.00%	100.00%
Description of Derivative Activity Volume Percent					60.00%	60.00%
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net						$ 9.0
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion		9.0	9.0	$ 9.0
Derivative Instruments, Gain (Loss) Recognized in Income, Net		(35.8)	97.4	12.0
Other Liabilities, Fair Value Disclosure		121.6				0.0	$ 50.0
Available-for-sale Securities, Gross Unrealized Gains		103.0				140.5
Available-for-sale Securities, Gross Unrealized Losses		80.0				29.0
Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value		2,498.9				5,246.0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value		2,164.4				2,102.0
Other than Temporary Impairment Losses, Investments	$ 12.2	26.8	12.0
Available-for-sale Securities, Gross Realized Gains	82.3	140.0	110.7
Available-for-sale Securities, Gross Realized Losses	10.9	9.9	4.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value						1,665.5
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value						4,776.5
Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value						373.9
Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value						754.0
Available-for-sale Securities, Debt Securities						7,569.9
Hedged Fixed-Rate Debt [Member]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge		51.5	259.6	149.6
Equity Contract [Member]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	$ 0.0	35.6	(35.6)
Interest Rate Contract [Member]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments		(51.5)	$ (259.6)	$ (149.6)
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Cash and Cash Equivalents, Fair Value Disclosure		5,922.5				4,018.8
Long-term Debt		(6,981.5)				(5,531.3)
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total		974.6				1,665.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total		4,029.8				6,313.3
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Interest Rate Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		6.1
Derivative Assets, Noncurrent		531.7				589.4
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		16.2				11.0
Carrying (Reported) Amount, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member] \| Other Liabilities [Member]
Derivative Liabilities, Current		(25.9)				(17.5)
Available-for-Sale Securities, Amortized Cost [Member]
Cash and Cash Equivalents, Fair Value Disclosure		5,922.5				4,018.8
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total		975.0				1,663.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total		4,006.4				6,203.8
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure		5,264.6				3,964.4
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure		657.9				54.4
Long-term Debt		(7,451.5)				(5,996.6)
Fair Value, Inputs, Level 2 [Member] \| Interest Rate Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		6.1
Derivative Assets, Noncurrent		531.7				589.4
Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member]
Derivative Liabilities, Current		(25.9)
Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		16.2				11.0
Fair Value, Inputs, Level 2 [Member] \| Foreign Exchange Contract [Member] \| Other Liabilities [Member]
Derivative Liabilities, Current						(17.5)
Estimate of Fair Value, Fair Value Disclosure [Member]
Cash and Cash Equivalents, Fair Value Disclosure		5,922.5				4,018.8
Long-term Debt		(7,451.5)				(5,996.6)
Estimate of Fair Value, Fair Value Disclosure [Member] \| Interest Rate Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		6.1
Derivative Assets, Noncurrent		531.7				589.4
Estimate of Fair Value, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member]
Derivative Liabilities, Current		(25.9)
Estimate of Fair Value, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member] \| Other Assets [Member]
Derivative Assets, Current		16.2				11.0
Estimate of Fair Value, Fair Value Disclosure [Member] \| Foreign Exchange Contract [Member] \| Other Liabilities [Member]
Derivative Liabilities, Current						(17.5)
Corporate Debt Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		600.7				1,503.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		2,081.3				3,351.3
Corporate Debt Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		601.1				1,501.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		2,093.3				3,322.9
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		600.7				1,503.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		2,081.3				3,351.3
Corporate Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		600.7				1,503.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		2,081.3				3,351.3
US Government Agencies Debt Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		362.3				150.2
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		908.8				1,362.7
US Government Agencies Debt Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		362.3				150.2
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		901.3				1,360.3
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		351.3				150.2
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		673.5				1,122.4
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		11.0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		235.3				240.3
US Government Agencies Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		362.3				150.2
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		908.8				1,362.7
Other Debt Obligations [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		11.6				11.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		10.0				3.3
Other Debt Obligations [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		11.6				11.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		11.9				3.3
Other Debt Obligations [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		11.6				11.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		8.7				3.3
Other Debt Obligations [Member] \| Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		1.3
Other Debt Obligations [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current		11.6				11.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		10.0				3.3
Collateralized Mortgage Backed Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		443.8				668.1
Collateralized Mortgage Backed Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		479.1				677.7
Collateralized Mortgage Backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		443.8				668.1
Collateralized Mortgage Backed Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		443.8				668.1
Asset-backed Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		245.0				519.0
Asset-backed Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		253.2				523.5
Asset-backed Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		245.0				519.0
Asset-backed Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent		245.0				519.0
Equity Securities [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		180.8				175.8
Equity Securities [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		107.5				83.0
Equity Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		180.8				175.8
Equity Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		180.8				175.8
Equity Method and Other Investments [Member] \| Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		160.1				233.1
Equity Method and Other Investments [Member] \| Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent		$ 160.1				233.1
Buy euro Sell US dollar [Member]
Notional Amount of Foreign Currency Derivative Purchase Contracts \| €					€ 212.0
Notional Amount of Foreign Currency Derivative Sale Contracts						277.4
Buy USD Sell Euro [Member]
Notional Amount of Foreign Currency Derivative Purchase Contracts						$ 273.8
Notional Amount of Foreign Currency Derivative Sale Contracts \| €					€ 210.0

Goodwill and Other Intangibles (Details) - USD ($) $ in Millions	12 Months Ended			36 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2012
Impairment of Intangible Assets, Finite-lived				$ 0.0
Goodwill, Impairment Loss	$ 0.0
Goodwill	1,501.3	$ 1,434.7		1,501.3
Intangible Assets, Gross	$ 1,566.3	1,909.6		1,566.3
Finite-Lived Intangible Assets, Weighted-Average Useful Life	9 years
Finite-Lived Intangible Assets, Amortization Expense	$ 563.0	469.0	$ 385.7
Future Amortization Expense, Year One	540.0			540.0
Future Amortization Expense, Year Two	530.0			530.0
Future Amortization Expense, Year Three	480.0			480.0
Future Amortization Expense, Year Four	380.0			380.0
Future Amortization Expense, Year Five	200.0			200.0
Impairment charges, indefinite lived intangibles	205.0	151.5	$ 0.0
In-process Research and Development [Member]
Intangible Assets, Gross	65.0	474.9		65.0
Developed Technology Rights [Member]
Intangible Assets, Gross	5,107.9	4,624.9		5,107.9
Intangible Assets, Accumulated Amortization and Other	1,987.0	1,481.2		1,987.0
Intangible Assets, Net	3,120.9	3,143.7		3,120.9
Other Intangible Assets [Member]
Intangible Assets, Gross	129.5	117.3		129.5
Intangible Assets, Accumulated Amortization and Other	64.0	42.5		64.0
Intangible Assets, Net	65.5	74.8		65.5
Finite-Lived Intangible Assets, Total [Member]
Intangible Assets, Gross	5,237.4	4,742.2		5,237.4
Intangible Assets, Accumulated Amortization and Other	2,051.0	1,523.7		2,051.0
Intangible Assets, Net	3,186.4	$ 3,218.5		$ 3,186.4
Amyvid [Member]
Finite-lived Intangible Assets Acquired	$ 190.0

Borrowings (Details) - USD ($) $ in Millions	12 Months Ended
Borrowings (Details) - USD ($) $ in Millions	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2010
Repayments of Long-term Debt	$ 1,500.6	$ 54.6	$ 1.1
Notes Payable	4,887.3	6,387.4
Other Notes Payable	37.4	37.6
Long-term Debt, Fair Value Adjustment	606.6	556.5
Long-term Debt, Total	5,531.3	6,981.5
Long-term Debt, Current Maturities	(11.9)	(1,516.8)
Long-term Debt, Excluding Current Maturities	5,519.4	5,464.7
Short-term Bank Loans and Notes Payable	$ 0.0	5.5		$ 125.0
Description of Derivative Activity Volume Percent	60.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 11.9
Long-term Debt, Maturities, Repayments of Principal in Year Two	1,010.0
Long-term Debt, Maturities, Repayments of Principal in Year Three	9.0
Long-term Debt, Maturities, Repayments of Principal in Year Four	203.9
Long-term Debt, Maturities, Repayments of Principal in Year Five	1,000.0
Line of Credit Facility, Remaining Borrowing Capacity	1,360.0
Line of Credit Facility, Collateral, Amount	1,200.0
Line of Credit Facility, Amount Outstanding	0.0
Interest Paid, Net	$ 171.9	$ 167.4	$ 176.3
Debt Instrument, Interest Rate, Effective Percentage	3.20%	3.00%
ESOP debentures, 6.55% [Member]
Other Notes Payable		$ 63.7
Debt Instrument, Interest Rate, Stated Percentage		6.55%

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Allocated Share-based Compensation Expense		$ 141.5	$ 147.4	$ 231.0
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense		$ 49.5	$ 51.6	$ 80.8
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		20 months
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		92,000
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		1,600	3,900	3,800
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	700
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 39.65
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		450.00%	490.00%	450.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum		0.36%	1.36%	1.36%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum		0.10%	0.20%	0.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum		22.40%	27.61%	28.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum		25.64%	29.10%	28.69%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Performance Awards, General [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 17.2
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		12 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 35.74	$ 31.90	$ 30.88
Shareholder Value Awards [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 48.2
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	2,400
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 30.35	$ 28.33	$ 25.97
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number		4,903	4,299	3,637	2,760
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1,742	1,830	1,987
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		(973)	(428)	(365)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		(165)	(740)	(745)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		6,900
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Restricted Stock Unit [Member]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized		$ 54.6
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		21 months
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		300	200	200
Share Based Compensation Arrangement by Share-based Payment Award, Expected Shares To Be Issued	900
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 35.80	$ 34.78
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		1,400	1,500	1,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Stock Option Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date		10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		27,232	36,556
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 63.89	$ 66.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		(50)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 20.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period		(9,274)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price		$ 73.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term		1 year 2 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 0.4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number		27,232
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 63.89
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term		1 year 2 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value		$ 0.4

Shareholders' Equity (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended				24 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2000	Dec. 31, 2011	Dec. 31, 2009
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 14,773.9	$ 13,535.6			$ 13,535.6
Common stock shares in treasury, shares in thousands	2,850	853			853
Net income	$ 4,088.6	$ 4,347.7	$ 5,069.5
Stock Repurchased During Period, Shares	16,918				0
Stock Repurchased During Period, Value	$ 819.2
Preferred Stock, Shares Authorized	5,000
Preferred Stock, Shares Issued	0
Common Stock, Shares Held in Employee Trust, Shares	50,000	50,000			50,000
Employee benefit trust	$ 3,013.2	$ 3,013.1			$ 3,013.1
Additional Paid-in Capital [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	4,963.1	4,886.8	4,798.5		4,886.8	$ 4,635.6
Treasury Stock, Retired, Cost Method, Amount		(0.1)	(1.0)
Stock Issued During Period, Value, Employee Benefit Plan	(65.2)	(108.7)	(87.6)
Stock Granted During Period, Value, Share-based Compensation, Net of Forfeitures	141.5	147.4	231.0
Employee Stock Ownership Plan (ESOP), Gain (Loss) on Transactions in Deferred Shares		49.7	20.5
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	16,088.2	14,897.8	12,732.6		14,897.8	9,830.4
Dividends, Common Stock, Cash	(2,186.5)	(2,182.5)	(2,167.3)
Treasury Stock, Retired, Cost Method, Amount	711.7
Deferred Costs, ESOP [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 0.0	0.0	(52.4)		$ 0.0	$ (77.4)
Employee Stock Ownership Plan (ESOP), Gain (Loss) on Transactions in Deferred Shares		$ 52.4	$ 25.0
Treasury Stock [Member]
Common stock shares in treasury, shares in thousands	2,850	853	864		853	882
Treasury Stock, Shares, Retired	(14,912)	(1)	(28)
Stock Issued During Period, Shares, Employee Benefit Plan	(9)	(10)	10
Treasury Stock, Value [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 192.4	$ 95.3	$ 96.4		$ 95.3	$ 98.5
Treasury Stock, Retired, Cost Method, Amount	(721.1)	(0.1)	(1.0)
Stock Issued During Period, Value, Employee Benefit Plan	(1.0)	$ (1.0)	$ (1.1)
2000 Share Repurchase Program [Member]
Accelerated Share Repurchases, Settlement Payment or Receipt	419.2
Stock Repurchased During Period, Value				$ 3,000.0
2012 Share Repurchase Program [Member]
Accelerated Share Repurchases, Settlement Payment or Receipt	400.0
Stock Repurchased During Period, Value	$ 1,500.0

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Earnings Per Share [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ 4,088.6	$ 4,347.7	$ 5,069.5
Weighted Average Number of Shares Outstanding, Basic	1,113,178	1,113,923	1,105,788
Earnings per share - basic	$ 3.67	$ 3.90	$ 4.58
Weighted Average Number of Shares Outstanding, Common Shares	1,117,294	1,113,967	1,105,813
Earnings per share - diluted	$ 3.66	$ 3.90	$ 4.58

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes (Composition and Deferreds) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Unremitted Earnings of Foreign Subsidiaries	$ 20,980.0
Current Federal Tax Expense (Benefit)	596.8	$ 671.4	$ 376.2
Current Foreign Tax Expense (Benefit)	540.6	759.5	513.9
Current State and Local Tax Expense (Benefit)	56.2	(22.9)	23.3
Current Income Tax Expense (Benefit), Total	1,193.6	1,408.0	913.4
Deferred Federal Income Tax Expense (Benefit)	87.0	(398.5)	624.4
Deferred Foreign Income Tax Expense (Benefit)	29.9	(34.7)	(55.2)
Deferred State and Local Income Tax Expense (Benefit)	9.1	27.0	(26.9)
Deferred Income Tax Expense (Benefit), Total	126.0	(406.2)	542.3
Income taxes	1,319.6	1,001.8	$ 1,455.7
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	1,081.8	1,286.5
Tax Credit Carryforward, Deferred Tax Asset	703.2	695.3
Deferred Tax Assets, Asset Purchases		386.2
Deferred Tax Assets, Operating Loss Carryforwards	370.1	406.1
Deferred Tax Assets, Goodwill and Intangible Assets	366.8
Deferred Tax Assets, Inventory	159.6	277.2
Deferred Tax Assets, Debt		214.9
Deferred Tax Assets, Deferred Income	278.6	207.1
Deferred Tax Assets, Hedging Transactions	232.8
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances	153.8	146.2
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies	113.2	94.5
Deferred Tax Assets, Other	361.5	292.8
Deferred Tax Assets, Gross, Total	3,821.4	4,006.8
Deferred Tax Assets, Valuation Allowance	(675.8)	(611.9)
Deferred Tax Assets, Net, Total	3,145.6	3,394.9
Deferred Tax Liabilities, Undistributed Foreign Earnings	(920.4)	(940.2)
Deferred Tax Liabilities, Goodwill and Intangible Assets	(708.8)	(797.6)
Deferred Tax Liabilities, Deferred Expense, Capitalized Inventory Costs	(573.4)	(489.2)
Deferred Tax Liabilities, Property, Plant and Equipment	(407.1)	(451.0)
Deferred Tax Liabilities, Derivatives	257.0
Deferred Tax Liabilities, Interests in Financial Assets Continued to be Held		(196.9)
Deferred Tax Liabilities, Total	2,866.7	2,874.9
Deferred Tax Assets (Liabilities), Net, Total	278.9	$ 520.0
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	100.7
Deferred Tax Assets, Tax Credit Carryforwards, Other	16.4
Carryforward [Member]
Operating Loss Carryforwards	737.5
Tax Credit Carryforward, Amount	973.2
Carryback [Member]
Tax Credit Carryforward, Amount	433.4
Expiration 5 years [Member]
Operating Loss Carryforwards	309.7
Expiration 5-20 years [Member]
Operating Loss Carryforwards	$ 394.5
Expiration 5-20 years, Minimum [Member]
Operating Loss Carryforwards, Expiration Dates	P5Y
Expiration 5-20 years, Maximum [Member]
Operating Loss Carryforwards, Expiration Dates	P20Y
Expiration 10-20 years [Member]
Tax Credit Carryforward, Amount	$ 0.7
Expiration 10-20 years, Minimum [Member]
Other Tax Carryforward, Expiration Dates	P10Y
Expiration 10-20 years, Maximum [Member]
Other Tax Carryforward, Expiration Dates	P20Y
No Expiration [Member]
Operating Loss Carryforwards	$ 33.4
Tax Credit Carryforward, Amount	3.7
Internal Revenue Service (IRS) [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	80.3
State and Local Jurisdiction [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	361.5
Foreign Tax Authority [Member] \| Designated Unusable [Member]
Tax Credit Carryforward, Amount	$ 93.6

Income Taxes (Income Tax Expense and Unrecognized Tax Benefits) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2010	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Abstract]
Domestic Contribution to Income before Income Taxes		54.00%	24.00%	45.00%
Income Taxes Paid		$ 992.0	$ 943.0	$ 861.0
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate		1,892.9	1,872.3	2,283.8
Income Tax Reconciliation, Deductions, Extraterritorial Income Exclusion		(593.8)	(796.7)	(823.3)
Income Tax Reconciliation, Additions, US Health Care Reform Tax Law		59.8	62.9	85.1
Income Tax Reconciliation, Tax Credits		(11.2)	(80.8)	(83.2)
Income Tax Reconciliation, Tax Settlements, Domestic		0.0	(85.3)	0.0
Income Tax Reconciliation, Other Adjustments		(28.1)	29.4	(6.7)
Income taxes		1,319.6	1,001.8	1,455.7
Income Tax Expense, Noncash Item, US Health Care Reform Act	$ 85.1
Unrecognized Tax Benefits, Beginning Balance	$ 1,351.2	1,274.8	1,619.6	1,351.2
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions		141.5	89.4	186.2
Unrecognized Tax Benefits, Increases Resulting from Prior Period Tax Positions		70.1	390.0	117.0
Unrecognized Tax Benefits, Decreases Resulting from Prior Period Tax Positions		(38.5)	(492.3)	(30.2)
Unrecognized Tax Benefits, Reductions Resulting from Lapse of Applicable Statute of Limitations		(4.6)	(2.6)	(7.0)
Unrecognized Tax Benefits, Decreases Resulting from Settlements with Taxing Authorities		(9.2)	(326.3)	(0.1)
Unrecognized Tax Benefits, Increases Resulting from Foreign Currency Translation		(0.3)	(3.0)	2.5
Unrecognized Tax Benefits, Ending Balance		1,433.8	1,274.8	1,619.6
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		928.1	812.3
Tax Adjustments, Settlements, and Unusual Provisions			85.3
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority			300.0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense		42.3	(47.3)	$ 38.3
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		$ 187.5	$ 134.6

Retirement Benefits (Schedule of Benefit Obligations and Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	$ 1,339.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,518.0	$ 1,339.0
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Benefit Obligation, Beginning Balance	9,191.2	8,115.0
Defined Benefit Plan, Service Cost	253.1	236.3	$ 219.2
Defined Benefit Plan, Interest Cost	455.1	447.9	431.6
Defined Benefit Plan, Actuarial Net (Gains) Losses	834.0	794.7
Defined Benefit Plan, Benefits Paid	(404.2)	(400.1)
Defined Benefit Plan, Plan Amendments	(0.6)	10.0
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	95.2	(12.6)
Defined Benefit Plan, Benefit Obligation, Ending Balance	10,423.8	9,191.2	8,115.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	7,186.3	6,983.0
Defined Benefit Plan, Actual Return on Plan Assets	922.7	209.2
Defined Benefit Plan, Contributions by Employer	469.7	402.4
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	112.1	(8.2)
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	8,286.6	7,186.3	6,983.0
Defined Benefit Plan, Funded Status of Plan	(2,137.2)	(2,004.9)
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	5,187.5	4,857.5
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	54.9	57.3
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	3,105.2	2,909.9
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Benefit Obligation, Beginning Balance	2,308.6	2,088.5
Defined Benefit Plan, Service Cost	63.3	72.4	56.5
Defined Benefit Plan, Interest Cost	114.9	118.0	121.4
Defined Benefit Plan, Actuarial Net (Gains) Losses	(57.0)	110.2
Defined Benefit Plan, Benefits Paid	(67.2)	(77.9)
Defined Benefit Plan, Plan Amendments	(28.4)	1.1
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Benefit Obligation	3.5	(3.7)
Defined Benefit Plan, Benefit Obligation, Ending Balance	2,337.7	2,308.6	2,088.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,339.0	1,327.7
Defined Benefit Plan, Actual Return on Plan Assets	183.4	16.6
Defined Benefit Plan, Contributions by Employer	62.8	72.6
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	0.0	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,518.0	1,339.0	$ 1,327.7
Defined Benefit Plan, Funded Status of Plan	(819.7)	(969.6)
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Gains (Losses), before Tax	1,156.7	1,367.4
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), Net Prior Service Cost (Credit), before Tax	(203.4)	(215.1)
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total	$ 133.6	$ 182.7

Retirement Benefits (Schedule of Components in Consolidated Balance Sheets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		$ 3,012.4	$ 3,068.5
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Amortization of Net Gains (Losses)	$ 395.4
Defined Benefit Plan, Current Assets		125.5	160.8
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities		(61.2)	(57.5)
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		2,201.6	2,108.2
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax		5,242.5	4,914.8
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total		3,105.2	2,909.9
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		285.7
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	3.1	(4.2)
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Current Assets		0.0	0.0
Pension and Other Postretirement Defined Benefit Plans, Current Liabilities		(8.9)	(9.3)
Pension and Other Postretirement Defined Benefit Plans, Liabilities, Noncurrent		810.8	960.3
Pension and Other Postretirement Benefit Plans, Accumulated Other Comprehensive Income (Loss), before Tax		953.3	1,152.3
Defined Benefit Plan, Amounts Recognized in Balance Sheet, Total		133.6	$ 182.7
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	96.2	98.4
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	$ 29.3	$ 39.8

Retirement Benefits (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Defined Benefit Plan, Health Care Cost Trend Rate Assumed for Next Fiscal Year	7.10%
Defined Benefit Plan, Direction and Pattern for Assumed Health Care Cost Trend Rate	0.30%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	5.00%
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.30%	5.00%	5.60%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	5.00%	5.60%	5.90%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase	3.40%	3.70%	3.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase	3.70%	3.70%	3.70%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.40%	8.50%	8.80%
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	4.30%	5.10%	0.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	5.10%	5.80%	6.00%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Return on Assets	8.80%	8.80%	9.00%

Retirement Benefits (Schedule of Expected Benefit Payments, Contributions and Expense) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Defined Benefit Plan, Accumulated Benefit Obligation		$ 9,460.0	$ 8,200.0
Defined Benefit Plan, Pension Plans with Accumulated Benefit Obligations in Excess of Plan Assets, Aggregate Accumulated Benefit Obligation		8,020.0	7,030.0
Defined Benefit Plan, Plans with Projected Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		6,890.0	5,960.0
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Benefit Obligation		9,150.0	8,120.0
Defined Benefit Plan, Plans with Benefit Obligations in Excess of Plan Assets, Aggregate Fair Value of Plan Assets		6,580.0	5,750.0
Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation		218.2
Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components		15.6
Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation		193.6
Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components		12.6
Defined benefit pension and retiree health benefit plans		128.6	1,240.2	$ (148.9)
Defined Contribution Plan, Cost Recognized		127.3	117.6	119.8
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		427.1
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		434.0
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		445.3
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		459.1
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		473.8
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		2,646.0
Defined Benefit Plan, Service Cost		253.1	236.3	219.2
Defined Benefit Plan, Interest Cost		455.1	447.9	431.6
Defined Benefit Plan, Expected Return on Plan Assets		(684.8)	(685.9)	(638.2)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		4.2	8.6	8.8
Defined Benefit Plan, Amortization of Gains (Losses)		285.7	200.4	163.0
Defined Benefit Plan, Amortization of Net Gains (Losses)	$ 395.4
Defined Benefit Plan, Net Periodic Benefit Cost, Total		313.3	207.3	184.4
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax		(598.9)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax		(0.6)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	3.1	(4.2)
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax		(285.7)
Foreign currency translation gains (losses)		19.3
Defined benefit pension and retiree health benefit plans		327.7
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		105.3
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		105.0
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		109.2
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		114.0
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		119.0
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		680.2
Defined Benefit Plan, Service Cost		63.3	72.4	56.5
Defined Benefit Plan, Interest Cost		114.9	118.0	121.4
Defined Benefit Plan, Expected Return on Plan Assets		(127.2)	(129.4)	(122.6)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)		(39.8)	(42.9)	(37.2)
Defined Benefit Plan, Amortization of Gains (Losses)		98.4	88.7	85.0
Defined Benefit Plan, Net Periodic Benefit Cost, Total		109.6	$ 106.8	$ 103.1
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax		113.2
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax		(28.4)
Other Comprehensive Income (Loss), Amortization, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Recognized in Net Periodic Benefit Cost, before Tax	29.3	39.8
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	$ (96.2)	(98.4)
Foreign currency translation gains (losses)		1.1
Defined benefit pension and retiree health benefit plans		(199.1)
Other Postretirement Benefit Plans, Defined Benefit, Gross [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		111.6
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		114.5
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		119.4
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		124.6
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		129.9
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		729.7
Other Postretirement Benefit Plans, Defined Benefit Plans, Medicare Rebates [Member]
Defined Benefit Plan, Expected Future Benefit Payments in Year One		(6.3)
Defined Benefit Plan, Expected Future Benefit Payments in Year Two		(9.5)
Defined Benefit Plan, Expected Future Benefit Payments in Year Three		(10.2)
Defined Benefit Plan, Expected Future Benefit Payments in Year Four		(10.6)
Defined Benefit Plan, Expected Future Benefit Payments in Year Five		(10.9)
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter		$ (49.5)

Retirement Benefits (Fair Value Disclosures) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Defined Benefit Plan, Percentage of Global Investments in Plan Assets	81.00%
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 1,518.0	$ 1,339.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,339.0
Defined Benefit Plan, Estimated Future Employer Contributions in Next Fiscal Year	60.0
Pension and Other Postretirement Benefit Contributions, Discretionary	300.0
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,518.0	1,339.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,339.0	1,327.7
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	8,286.6	7,186.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	7,186.3	6,983.0
Equity Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	81.9	40.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	40.9
Equity Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	991.2	454.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	$ 454.5
Equity Securities [Member]
Defined Benefit Plan, Target Allocation Percentage of Assets	80.00%
Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 45.4	79.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	79.9
Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	457.7	870.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	870.2
Equity Securities, International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	127.7	97.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	97.1
Equity Securities, International [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,905.3	1,462.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,462.4
Fixed Income Funds, Developed Markets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	59.4	55.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	55.3
Fixed Income Funds, Developed Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,075.4	929.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	929.1
Fixed Income Funds, Emerging Markets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	40.3	34.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	34.6
Fixed Income Funds, Emerging Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	402.3	341.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	341.5
Hedge Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	234.0	213.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	213.1
Hedge Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,555.5	2,312.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,312.6
Real Estate [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	35.4	27.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	27.5
Real Estate [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	504.3	409.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	409.2
Other Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	24.8
Other Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	394.9
Other Contract [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	869.1	767.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	767.9
Other Plan Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		22.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	22.7
Other Plan Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		406.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	$ 406.8
Debt Securities [Member]
Defined Benefit Plan, Target Allocation Percentage of Assets	20.00%
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	$ 105.9	91.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	91.6
Fair Value, Inputs, Level 1 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,648.6	1,373.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,373.0
Fair Value, Inputs, Level 1 [Member] \| Equity Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		28.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	28.0
Fair Value, Inputs, Level 1 [Member] \| Equity Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	17.4	317.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	317.2
Fair Value, Inputs, Level 1 [Member] \| Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	30.4
Fair Value, Inputs, Level 1 [Member] \| Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	307.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance
Fair Value, Inputs, Level 1 [Member] \| Equity Securities, International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	33.9	27.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	27.5
Fair Value, Inputs, Level 1 [Member] \| Equity Securities, International [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	673.3	505.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	505.9
Fair Value, Inputs, Level 1 [Member] \| Fixed Income Funds, Developed Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	156.4	100.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	100.9
Fair Value, Inputs, Level 1 [Member] \| Fixed Income Funds, Emerging Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		0.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.1
Fair Value, Inputs, Level 1 [Member] \| Real Estate [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	35.4	27.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	27.5
Fair Value, Inputs, Level 1 [Member] \| Real Estate [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	353.5	271.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	271.2
Fair Value, Inputs, Level 1 [Member] \| Other Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	6.2
Fair Value, Inputs, Level 1 [Member] \| Other Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	140.1
Fair Value, Inputs, Level 1 [Member] \| Other Plan Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		8.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	8.6
Fair Value, Inputs, Level 1 [Member] \| Other Plan Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		177.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	177.7
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,229.9	1,062.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,062.2
Fair Value, Inputs, Level 2 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	4,363.1	3,556.7
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	3,556.7
Fair Value, Inputs, Level 2 [Member] \| Equity Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		12.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	12.9
Fair Value, Inputs, Level 2 [Member] \| Equity Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	63.3	137.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	137.3
Fair Value, Inputs, Level 2 [Member] \| Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	15.0
Fair Value, Inputs, Level 2 [Member] \| Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	149.8
Fair Value, Inputs, Level 2 [Member] \| Equity Securities, International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	93.8	69.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	69.6
Fair Value, Inputs, Level 2 [Member] \| Equity Securities, International [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,232.0	956.5
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	956.5
Fair Value, Inputs, Level 2 [Member] \| Fixed Income Funds, Developed Markets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	59.0	55.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	55.3
Fair Value, Inputs, Level 2 [Member] \| Fixed Income Funds, Developed Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	915.3	828.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	828.2
Fair Value, Inputs, Level 2 [Member] \| Fixed Income Funds, Emerging Markets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	40.3	34.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	34.6
Fair Value, Inputs, Level 2 [Member] \| Fixed Income Funds, Emerging Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	402.3	341.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	341.4
Fair Value, Inputs, Level 2 [Member] \| Hedge Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	134.1	107.8
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	107.8
Fair Value, Inputs, Level 2 [Member] \| Hedge Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,337.4	1,064.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,064.2
Fair Value, Inputs, Level 2 [Member] \| Real Estate [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	8.2
Fair Value, Inputs, Level 2 [Member] \| Other Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	18.6
Fair Value, Inputs, Level 2 [Member] \| Other Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	254.8
Fair Value, Inputs, Level 2 [Member] \| Other Contract [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	869.1	767.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	767.9
Fair Value, Inputs, Level 2 [Member] \| Other Plan Assets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		14.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	14.1
Fair Value, Inputs, Level 2 [Member] \| Other Plan Assets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		229.1
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	229.1
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	182.2	185.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	185.2
Fair Value, Inputs, Level 3 [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	182.2	185.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	185.2	181.1
Defined Benefit Plan, Actual Return on Plan Assets Still Held	(0.9)	3.8
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0	(1.8)
Defined Benefit Plan, Purchases, Sales, and Settlements	(2.2)
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		2.1
Defined Benefit Plan, Transfers Between Measurement Levels	0.1
Fair Value, Inputs, Level 3 [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	2,274.9	2,256.6
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	2,256.6	2,171.3
Defined Benefit Plan, Actual Return on Plan Assets Still Held	32.0	30.2
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(0.2)	(18.1)
Defined Benefit Plan, Purchases, Sales, and Settlements	(14.6)
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		73.2
Defined Benefit Plan, Transfers Between Measurement Levels	1.1
Fair Value, Inputs, Level 3 [Member] \| Equity Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	81.9	79.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	79.9	74.5
Defined Benefit Plan, Actual Return on Plan Assets Still Held		3.3
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period		0.0
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		2.1
Fair Value, Inputs, Level 3 [Member] \| Equity Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	910.5	870.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	870.2	802.9
Defined Benefit Plan, Actual Return on Plan Assets Still Held		34.4
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period		0.0
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		32.9
Fair Value, Inputs, Level 3 [Member] \| Equity Securities [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		79.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	79.9
Fair Value, Inputs, Level 3 [Member] \| Equity Securities [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance		870.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	870.2
Fair Value, Inputs, Level 3 [Member] \| Equity Securities, International [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	81.9	79.9
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	79.9
Defined Benefit Plan, Actual Return on Plan Assets Still Held	0.0
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0
Defined Benefit Plan, Purchases, Sales, and Settlements	2.0
Defined Benefit Plan, Transfers Between Measurement Levels	0.0
Fair Value, Inputs, Level 3 [Member] \| Equity Securities, International [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	910.5	870.2
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	870.2
Defined Benefit Plan, Actual Return on Plan Assets Still Held	10.1
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0
Defined Benefit Plan, Purchases, Sales, and Settlements	30.2
Defined Benefit Plan, Transfers Between Measurement Levels	0.0
Fair Value, Inputs, Level 3 [Member] \| Fixed Income Funds, Developed Markets [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	0.4	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Actual Return on Plan Assets Still Held	0.0
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0
Defined Benefit Plan, Purchases, Sales, and Settlements	0.3
Defined Benefit Plan, Transfers Between Measurement Levels	0.1
Fair Value, Inputs, Level 3 [Member] \| Fixed Income Funds, Developed Markets [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	3.7	0.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	0.0
Defined Benefit Plan, Actual Return on Plan Assets Still Held	0.3
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0
Defined Benefit Plan, Purchases, Sales, and Settlements	2.3
Defined Benefit Plan, Transfers Between Measurement Levels	1.1
Fair Value, Inputs, Level 3 [Member] \| Hedge Funds [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	99.9	105.3
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	105.3	106.6
Defined Benefit Plan, Actual Return on Plan Assets Still Held	(0.9)	0.5
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0	(1.8)
Defined Benefit Plan, Purchases, Sales, and Settlements	(4.5)
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		0.0
Defined Benefit Plan, Transfers Between Measurement Levels	0.0
Fair Value, Inputs, Level 3 [Member] \| Hedge Funds [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	1,218.1	1,248.4
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	1,248.4	1,241.9
Defined Benefit Plan, Actual Return on Plan Assets Still Held	18.3	(8.1)
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	(0.2)	(18.1)
Defined Benefit Plan, Purchases, Sales, and Settlements	(48.4)
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		32.7
Defined Benefit Plan, Transfers Between Measurement Levels	0.0
Fair Value, Inputs, Level 3 [Member] \| Real Estate [Member] \| Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance
Defined Benefit Plan, Actual Return on Plan Assets Still Held
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets
Fair Value, Inputs, Level 3 [Member] \| Real Estate [Member] \| Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Fair Value of Plan Assets, Ending Balance	142.6	138.0
Defined Benefit Plan, Fair Value of Plan Assets, Beginning Balance	138.0	126.5
Defined Benefit Plan, Actual Return on Plan Assets Still Held	3.3	3.9
Defined Benefit Plan, Actual Return on Plan Assets Sold During Period	0.0	0.0
Defined Benefit Plan, Purchases, Sales, and Settlements	1.3
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		$ 7.6
Defined Benefit Plan, Transfers Between Measurement Levels	$ 0.0

Contingencies (Details)	12 Months Ended
Contingencies (Details)	Dec. 31, 2012
Product Liability Litigation [Member] \| Zyprexa [Member]
Loss Contingency, Number of Lawsuits	10
Loss Contingency, Number of Plaintiffs	10
Product Liability Litigation [Member] \| Byetta [Member]
Loss Contingency, Number of Claimants	465
Loss Contingency, Number of Lawsuits	140
Loss Contingency, Number of Plaintiffs	520
Product Liability Litigation [Member] \| Diethylstilbestrol [Member]
Loss Contingency, Number of Lawsuits	90
Loss Contingency, Number of Plaintiffs	90
Damages From Product Breast Cancer [Member] \| Diethylstilbestrol [Member] \| Product Liability Litigation [Member]
Loss Contingency, Number of Claimants	80
California [Member] \| Product Liability Litigation [Member] \| Byetta [Member]
Loss Contingency, Number of Lawsuits	100
Loss Contingency, Number of Plaintiffs	485

Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (3,797.1)	$ (3,858.6)
Other Comprehensive Income (Loss), Net of Tax	61.5	(1,188.5)	$ (198.2)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Tax	34.4	(383.8)	60.4
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	30.8	(64.4)	27.3
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax		32.6	(9.3)
Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax	(46.4)	(54.7)	(27.6)
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax	5.9	(5.8)	(5.8)
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(3,797.1)	(3,858.6)	(2,670.1)	$ (2,471.9)
Other Comprehensive Income (Loss), Net of Tax	61.5	(1,188.5)	(198.2)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax	426.8	265.9	510.7	835.8
Other Comprehensive Income (Loss), Net of Tax	160.9	(244.8)	(325.1)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax	72.5	14.8	128.9	75.4
Other Comprehensive Income (Loss), Net of Tax	57.7	(114.1)	53.5
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax	104.1	(59.4)	81.1
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(4,195.2)	(4,032.2)	(3,175.8)	(3,264.3)
Other Comprehensive Income (Loss), Net of Tax	(163.0)	(856.4)	88.5
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax	(101.2)	(107.1)	(133.9)	$ (118.8)
Other Comprehensive Income (Loss), Net of Tax	$ 5.9	$ 26.8	$ (15.1)

Other - Net, Expense (Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Other Revenue, Net	$ 633.0	$ 681.7	$ 633.8
Income related to prepayment of revenue-sharing obligation	(787.8)	0.0	0.0
Interest Expense	177.8	186.0	185.5
Investment Income, Interest	(105.0)	(79.9)	(51.9)
Other (income)expense	41.0	72.9	(128.6)
Nonoperating Income (Expense), Total	(674.0)	179.0	5.0
Exenatide [Member]
Other Revenue, Net	70.1	$ 243.1	$ 262.5
Other (income)expense	$ (787.8)